Multi-Functional Mucosal Vaccine Platform

ABSTRACT

An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more FcyRI-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more FcRn-binding domains.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 61/938,607, filed Feb. 11, 2014, the entire content of which are hereby incorporated by reference.

STATEMENT OF FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

This invention was made with government support under Grant No. 5R01 AI076408-04 awarded by the National Institute of Health. The government has certain rights in the invention.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

Incorporated by reference in its entirety herein is a computer-readable sequence listing submitted concurrently herewith and identified as follows: One 114,302 Byte ASCII (Text) file named “seq_listing.txt,” created on Feb. 11, 2015.

BACKGROUND

The majority of human pathogens enter via mucosal sites. Thus, there is a significant need for novel vaccine technologies that can generate robust mucosal immunity. However, adjuvants are currently required to accomplish this. Yet, adjuvants applied to mucosal tissue increase the risk of unwanted inflammatory effects, toxicity, and may even increase susceptibility to infection.

U.S. Publication No. 20120258092 to Dahiyat relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.

U.S. Patent Application Publication No. 2009/0280181 to Slager relates to particles with nucleic acid complexes, medical devices including the same and related methods.

U.S. Pat. No. 7,459,531 to Moore relates to human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins.

U.S. Pat. No. 6,248,332 to Gosselin relates to methods of stimulating in a subject an immune response to an Ag to which the immune response is targeted. This method includes the step of administering to the subject a binding agent, which binds a surface receptor of an APC, and an Ag to which the immune response is targeted.

U.S. Pat. No. 6,258,358 to Gosselin relates to methods of stimulating in a subject an immune response to an Ag to which the immune response is targeted. Also disclosed are molecular complexes including the binding agent coupled to an Ag.

U.S. Pat. No. 7,316,812 to Keler relates to cells transformed to express on their surface a component, which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.

U.S. Pat. No. 7,378,504 relates to isolated monoclonal Abs, such as human Abs that bind to CD64 with high affinity. Nucleic acid molecules encoding the Abs of the invention, expression vectors, host cells and methods for expressing the Abs of the invention are also disclosed.

U.S. Publication No. 20040109874 to Fuller relates to methods for generating an immune response at a mucosal surface.

However, none of the aforementioned documents appear to disclose or suggest using a fusion protein with binding domains FcγRI+FcRn as an adjuvant-free muscosal vaccine.

This background information is provided for informational purposes only. No admission is necessarily intended, nor should it be construed, that any of the preceding information constitutes prior art against the present invention.

SUMMARY

In one aspect, the vaccine platform will allow non-invasive, single dose, and highly efficient vaccine delivery to the nasal mucosa, thereby stimulating robust mucosal immunity in the absence of traditional adjuvant. This vaccine platform will have wide application not only against common pathogens such as Streptococcus pneumonia and influenza, but also emerging, re-emerging, and biodefense pathogens.

One embodiment involves the development of a unique multi-functional non-adjuvanted mucosal vaccine platform that will maximize mucosal and systemic immune responses (cellular and humoral), eliminate the need for adjuvant, eliminate the requirement for a cold chain, enable safe intranasal delivery of vaccines, as well as provide a vaccine platform that can be employed to develop vaccines against a wide range of pathogens and in particular, superior protection against pathogens that infect via the mucosal route. To accomplish these goals, this vaccine will comprise a DNA and/or recombinant fusion protein (FP) vaccine. In the case of the DNA form, in some embodiments, the DNA will be administered intranasally as a single dose and induce expression of an Fc receptor (FcR)-targeted FP. Alternative approaches will include: an FcR-targeted DNA prime-FP boost vaccine, a combined FcR-targeted DNA plus FP vaccine, or an FcR-targeted FP prime-FP boost vaccine. In some embodiments, the vaccine will be administered intranasally as either a liquid mist or powder lyophilized or precipitated onto carrier particles. When administered as a DNA vaccine, in some embodiments, the plasmid encoding the FP will transfect mucosal epithelial cells along the nasal mucosa within the upper respiratory tract, resulting in local expression of FcR-targeted FP containing the antigen (Ag). In some embodiments, the FP itself will comprise three functional components/elements (be multi-functional in nature) (FIG. 1). The first component will be the Ag/immunogen. The Ag will be fused to a neonatal FcR (FcRn)-targeting element. FcRn can mediate the transport of IgG and serum albumin from the lumen of the mucosal tract to the underlying nasal associated lymphoid tissue (NALT). In one embodiment, the FcRn-targeting element will therefore function in providing direct transport of the Ag-containing FP to the NALT. Within the NALT are Ag presenting cells (APCs), which are key to generating an effective mucosal and peripheral immune response to intranasally administered immunogens/Ags. To increase targeting of the immunogen to APCs, the Ag within the FP will also fused to a humanized human FcγRI-specific multi-valent scFv (APC)-targeting element. FcγRI is primarily expressed on two key APCs: macrophages and dendritic cells (DCs), which are involved in initiation and maintenance of the adaptive immune response. Thus, fusing the Ag to an FcγRI targeting element will target the Ag directly to the APCs for enhanced DC maturation, Ag processing, Ag presentation, and Ag-specific T cell activation, following transport of the FP to the NALT via FcRn. Flexible linkers can be attached to either side of the Ag in an effort to minimize steric interference between FP components (Ag and targeting elements). The ability of the vaccine to both mediate Ag transport to the NALT and subsequently target APCs within the NALT, is a unique feature of this vaccine that will maximize its potency and eliminate the need for an adjuvant. In summary, this FP vaccine, which could be administered as either a DNA or protein form and in a regimen consisting of DNA alone, protein alone, or a combination of the two consisting of either a consecutive DNA prime followed by a protein boost (DNA+protein) or DNA and protein at the same time (DNA/protein) will initiate a unique sequence of events (FIG. 1): 1) In the case of the DNA, DNA+protein, or DNA/protein, the vaccine will result in transfection of epithelial cells lining the nasal mucosal and the production and secretion of Ag-containing FP by these cells. 2) In the case of both DNA and protein forms, immunization will result in enhanced transport of the FP via FcRn to the NALT and targeting of Ag-containing FPs to APCs within the NALT via FcγRI. Consequently, the presence of the Ag-containing FP in the nasal mucosal tissue will induce both humoral and cellular immunity at mucosal and parenteral sites. The use of the protein form of FP will not depend on successful transfection of the epithelial cells. On the other hand, successful transfection of nasal epithelial cells with the FP in a DNA vaccine form will provide a number of advantages including rapid and inexpensive production and, since DNA vaccines are stable at room temperature, elimination of the requirement for a cold chain and stockpiling of the vaccine. Similarly, use of FP in protein vaccine form either alone or in combination with a DNA vaccine should minimize the need for a cold chain, since refrigeration is generally required to maintain stability of protein-adjuvant formulations and the FP vaccine does not require an adjuvant. In all instances, toxicities and adverse events associated with nasal vaccines containing live viral vectors or adjuvants would be significantly reduced or eliminated.

This strategy can be employed for any pathogen and is therefore a vaccine platform technology. The vaccine platform will provide a particular advantage over existing vaccines in protection against pathogens that are transmitted via the respiratory route (i.e. influenza, RSV, tuberculosis, Streptococus pneumoiae, etc.). In addition, since intranasal immunization results in the induction of mucosal responses in other compartments (i.e vagina, gut) and in the blood, the technology could also be used to develop vaccines against sexually transmitted pathogens (i.e. HIV, Chlamydia, etc.), orally transmitted pathogens (i.e. Hepatitis A, Helicobacter pylori) and blood-borne pathogens (i.e. vector borne pathogens, such as dengue and pathogens transmitted via needle sticks, such as HBV). As indicated above, the vaccine is designed to maximize Ag transport to the NALT and subsequently Ag presentation/T cell activation within the NALT, resulting in an efficient mechanism to induce both local mucosal as well as systemic humoral and cellular immunity. This technology will solve several challenges that currently cannot be met by existing technologies: 1) Most vaccines are administered systemically (injected with a needle) and induce immune responses primarily in the periphery providing a defense against a respiratory pathogen only after it has disseminated from the periphery into the mucosa. In contrast, the proposed FP vaccine will induce superior protection against pathogens transmitted via a mucosal route by inducing immune responses that block or abort transmission at the site of mucosal exposure. 2) Existing licensed or experimental vaccines require either a live attenuated virus or adjuvant to stimulate protective levels of immunity, but at the expense of inducing inflammatory responses that reduce their tolerability and safety, especially when administered intranasally. In contrast, in one embodiment, the FP vaccine does not require an adjuvant, so it can be safely administered intranasally and induce mucosal immunity with minimal risk. 3) Most DNA vaccines are poorly immunogenic due, in part, to lack of inherent immunostimulatory properties and the low amount of Ag produced. Current efforts to overcome the poor immunogenicity of DNA vaccines include delivery of multiple doses, co-administration of the DNA vaccine with an adjuvant, and/or boosting DNA vaccine primed responses with a different vaccine modality. In contrast, in one embodiment, the FP vaccine in a DNA form will overcome these issues by directly targeting the small amounts of Ag-containing FP produced by the DNA vaccine to the NALT and APCs within the NALT. In this way, the expressed Ag is more efficiently processed and presented to the immune systemic leading to more robust immunogenicity without the need for high Ag doses or a second vaccine modality. In addition, targeting Ag to the APCs results in activation of these cells without the need for an adjuvant. 4) Using the FP vaccine in either DNA or protein form and administered as either DNA or protein alone or in combination (DNA+protein, DNA/protein) will provide advantages over similar vaccine concepts administered as non-targeted recombinant protein, killed, or live attenuated vaccines. Specifically, DNA vaccines are stable at room temperature so they can be distributed without a cold chain. In addition, DNA vaccines can be rapidly scaled up with relatively minimal cost providing a more cost effective approach for wide-spread vaccination. Due to the lack of requirement for adjuvant, the protein form of the FP vaccine should provide similar advantages, Furthermore, in the event of an emerging pandemic, a FP vaccine will be able to achieve more rapid intervention than other vaccine modalities because production of the vaccine will require only the pathogen's sequence from a clinical isolate and once identified, FP vaccines can be propagated in a very short (FP as DNA) or shorter (FP as protein) period of time using well-established molecular and recombinant techniques, without the need for extensive or complex purification steps. Since both the DNA and protein forms of the FP vaccines are non-replicating, they are also safer and can be more rapidly manufactured and distributed without the need for the more extensive safety tests currently required for killed or live attenuated vaccines. In addition, the FP vaccine should be more immunogenic with fewer doses, reducing the need for repeat immunizations, further increasing patient compliance and safety profile of the vaccine.

This will be the first instance of a mucosal vaccine employing FP as either a DNA or protein vaccine form, which targets both FcRn and FcγRI. More generally, to our knowledge, expression/use of FP vaccine designed to both target Ag to the NALT via the FcRn transeptithelial transport pathway, and subsequently to APCs within the NALT via FcγRI, has not been tested or published. Furthermore, DNA vaccination is not an obvious choice for this approach because, in the absence of FcR targeting, DNA vaccines are poorly immunogenic and require high doses to induce an immune response that cannot be achieved via intranasal delivery. In fact, most DNA vaccines are administered via the intramuscular route and designed to express and present the Ag primarily in the muscle cells not nasal cells in vivo. Therefore, a DNA vaccine, which produces a FP that targets the Ag to APC in a mucosal compartment, is not obvious and is novel. Furthermore, the expression of the FP by a DNA vaccine, which targets enhanced delivery of the Ag (via FcRn-targeted FP) to the NALT, and subsequently APCs within the NALT will likely overcome poor immunogenicity of DNA vaccines, thus providing a novel method to overcome current limits of DNA vaccines. Based on current state of art, people would also not combine the three FP components (Anti-FcγRI-Ag-anti-FcRn) into a single FP. However, we have thus far demonstrated we can generate an FP that maintains FcRn and FcγRI targeting functions. Furthermore, an FP DNA vaccine will provide two concurrent mechanisms for Ag presentation—first, in the cells transfected and adjacent interdigitating DCs, and second, in the APCs within the NALT targeted by the expressed Ag-containing FP. This dual Ag presentation will not only increase immunogenicity, but should also expose a broader range of antigenic epitopes than a traditional recombinant protein or DNA vaccine, resulting in a broader specificity in the immune response that will be more effective for protection. DNA vaccine transfection of nasal epithelium in vivo will also provide an advantage over nasal delivery of killed or live attenuated vaccines because presentation in these vaccine forms is very transient, whereas a DNA vaccine can express Ag in the transfected cells for days or weeks, thus providing longer term exposure in vivo to the vaccine Ag and targeting of the Ag to APCs within the NALT. This effect should translate into more durable immunity when compared to mucosal administration of non-targeted protein-based vaccines. Taken together, the vaccine strategy will result in a unique sequence of events (FIG. 1) that have not yet been demonstrated as possible or replicated by current traditional approaches for vaccination.

In some embodiments the mucosal vaccine platform can be broadly employed for any pathogen, especially those transmitted via the respiratory route. Gene delivery in the case of CF or drug delivery are also contemplated.

Some embodiments inhere advantages, for example: 1) Improve potency of DNA vaccines; 2) Eliminates the cold chain; 3) Non-invasive administration; 4) Eliminates adjuvant/potential toxicity; 5) Reduced dose, administrations, and thus cost and potential for adverse effects; 6) No adjuvant and no live replicating vectors so increased safety profile (minimal risk for inflammation, no risk of reversion); 7) Can generate both humoral and cellular immunity; 8) Can generate both mucosal and peripheral immunity; 9) Mucosal immunity induced by the vaccine is expected to confer enhanced protection against mucosally transmitted pathogens when compared to existing vaccines that induce responses only in the periphery; 10) Universal vaccine platform that will be applicable to bacterial and viral as well as mucosal and non-mucosal pathogens; 11) Likely increased compliance due to elimination of booster immunizations and injection with needle.

It is to be understood that both the foregoing summary and the following descriptions are exemplary, and thus do not restrict the scope of the embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 graphically presents predicted trafficking of one embodiment of the hFcRn/hFcγRI-Targeted FP.

FIG. 2 presents data wherein anti-hFcγRI-PspA FP enhances protection against Sp challenge in hFcγRI Tg mice, in the absence of adjuvant. C57BL/6 hFcγRI Tg mice (5-8 mice/group) were immunized i.n. with PBS or 25 ng of anti-hFcγRI-PspA FP (day 0) and boosted on days 14 and 28. Two weeks post-final boost, mice were challenged i.n. with Sp (1×10⁶ CFU), and survival was monitored for 21 days. Representative survival curves from a minimum of 3 experiments are presented. p<0.005 (PBS vs. anti-hFcγRI-PspA FP-immunized group).

FIG. 3 presents data wherein targeting PspA to hFcγRI enhances Sp-specific Ab responses in hFcγRI Tg mice. C57BL/6 WT and hFcγRI Tg mice (4-6/group) were immunized i.n. with PBS or with 25 μg of bivalent anti-hFcγRI-PspA (day 0) and boosted on days 14 and 28. On day 42 serum and BAL were collected, and the Sp-specific IgG (A) and IgA (B) were measured by ELISA, respectively. Results are representative of 2 independent experiments (*, P<0.1; **, P<0.05).

FIG. 4 graphically presents a status of some embodiments of FP and DNA Vaccine Constructs.

FIG. 5 presents data wherein trivalent anti-hFcγRI-PspA binds hFcγRI and bivalent anti-hFcγRI-PspA-HSA binds hFcγRI and hFcRn: Supernatants from FP transfected NSO cells were screened for FP binding to hFcRn and/or hFcγRI by ELISA. To hFcγRI-coated wells (A), media or NSO supernatant from non-transfected and FP transfected cells were added overnight at 4° C. followed by 3 washes, addition of Rb anti-PspA or Rb anti-HSA Ab for 2 hrs at 4° C., 3 washes, goat anti-Rb IgG-AP for 2 hrs at 4° C., 3 washes, and AP substrate at room temperature. To hFcRn coated wells (B), supernatants were added and the above process repeated using Rb anti-PspA Ab only. In this case, all reagents, including supernatants, were adjusted to pH 6.0 (required for FcRn binding). ODs from media controls were subtracted from sample ODs. FP concentrations were not equalized for these assays, potentially explaining signal variability between FP samples. * P<0.05, ***p<0.0001.

FIG. 6 graphically presents one embodiment of anti-hFcγRI-Ag FPs lacking the Fc domain, with the Fab regions also binding outside the IgG-Fc binding site

FIG. 6a graphically presents some embodiments of current and proposed FP formulations.

FIG. 7 presents data wherein DNA for PspA and bivalent anti-hFcγRI-PspA FP was inserted into pJV7563 (3.759 kb) to produce pJV7563-pspa (4.665 kb) and pJV7563-anti-hFcγRI-pspa (6.333 kb). The plasmid DNA was linearized by digestion with NheI before agarose gel electrophoresis.

FIG. 8 presents data wherein secretion of soluble PspA (sPspA) and soluble anti-hFcγRI-PspA FP (sAnti-hFcγRI-PspA) by cells transfected with DNA vaccine vectors. NIH-3T3 (Mouse-embryonic fibroblast) cells were transfected with DNA lipofectamine complexes. After 72 h incubation, supernatants were harvested. Total proteins in supernatants were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were then incubated sequentially with PspA specific Ab and then AP-conjugated secondary Ab. The nitrocellulose membranes were then developed with 5-bromo-4-chloro-3-indolyl-phosphate-nitrobluetetrazolium substrate. Empty vector (Vector) and purified recombinant PspA (rPspA) were used as negative and positive controls, respectively. Molecular weight markers are also depicted (M).

FIG. 9 presents data wherein generation of Sp-specific IgG following i.n. immunization with PspA versus anti-hFcγRI-PspA FP DNA vaccine using hFcγRI Tg versus WT mice. Human FcγRI Tg or WT mice were immunized with empty vector, vector containing PspA DNA, or vector containing anti-hFcγRI-PspA FP DNA. Each DNA vaccine was mixed with PolyEthyleneImine (PEI) and 5% Glucose, and kept for 15 mm at room temperature for DNA-PEI complex formation prior to administration. Mice 6-8 weeks of age were then immunized by i.n. route on days 0 and 28. Specifically, mice were anesthetized and 40 μl of PEI-DNA complex containing 4.2 pmole DNA was administered drop-wise into alternating nostrils. Sera were collected 14 days post-boost. In this preliminary study, data represents the mean of 3 mice/group±SE. Additional studies will now be conducted with 8 mice per group.

FIG. 10 presents data wherein one embodiment of mAb 22.2 from which the anti-hFcγRI-PspA FP was generated, also cross-reacts with NHP FcγRI. Anti-hFcγRI mAbs 22.2 (red) and 10.1, recognize and bind to FcγRI on NHP PBMCs. Isoptype controls are blue.

FIG. 11 presents data wherein trivalent and HSA-containing FPs bind hFcγRI on hFcγRI-expressing U937 cells: Supernatants from FP construct-transfected NSO cells were screened by flow cytometry for the presence of FPs and the ability of trimeric and HSA-containing/FcRn-binding FPs to bind hFcγRI on U937 cells. Briefly, hFcγRI-expressing U937 cells were incubated for 2 hrs at 4° C. with culture medium, supernatant from non-transfected NSO cells, or supernatant from FP transfected cells in the presence of human IgG (to block non-specific FcR binding of Rb Abs), followed by 3 washes, a 1 h incubation with Rb anti-PspA or Rb anti-HSA Ab, 3 washes, and a 30 min incubation with goat anti-Rb IgG-FITC. Cells were then washed, fixed, and analyzed by flow cytometry. **P<0.005, ***p<0.0001.

FIG. 12 graphically presents one embodiment of a map of pJG582 Vector. The pJG582 vector contains four tandem 5′ to 3′ DNA sequences encoding humanized VL-VH-VL-VH ScFv fragments derived from the humanized 22 (anti-human FcγRI) monoclonal antibody. These segments are joined by flexible linker sequences and flanked on the 5′ end by a CMV promoter, which induces FP production by eukaryotic cells. 3′ of the above V segments are XhoI/NotI restriction sites between which DNA sequences encoding antigen, such as PspA, or other molecules, can be inserted. 3′ of the XhoI/NotI insertion site is a neo resistance gene used for selection of transfected cells expressing the desired FP. In addition, within this vector is a signal sequence, which directs secretion of the FP by eukaryotic cells producing it.

FIG. 13 graphically presents some embodiments of status of FP and DNA Vaccine Constructs.

FIG. 14 graphically presents one embodiment of a map of pJV-7563 Vector (No secretion signal). Note: The sequences for PspA or the anti-human FcγRI-PspA fusion proteins have been inserted between NheI and Bgl-II restriction sites.

FIG. 15 graphically presents one embodiment of a map of pUW-160s Vector (Contains secretion signal). This Plasmid has a Lysozyme secretion signal (Labeled as Lysozyme SP), which facilitates secretion of attached polypeptides through plasma membranes. Note: While making vaccine constructs the stuffer fragment has been replaced with either PspA or anti-human FcγRI-PspA fusion protein.

FIG. 16 graphically presents embodiments of constructs in trivalent Anti-FcγRI-PspA.

FIG. 17 graphically presents embodiments of constructs in bivalent Anti-FcγRI-PspA-HuSA.

FIG. 18 graphically presents embodiments of constructs in trivalent Anti-FcγRI-PspA-HuSA.

FIG. 19 graphically presents embodiments of constructs in non-FcγRI-Targeted PspA-HuSA.

DETAILED DESCRIPTION OF THE SEVERAL EMBODIMENTS

Reference will now be made in detail to several embodiments which, together with the drawings and the examples herein, serve to better describe the invention in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized, and that structural, biological, and chemical changes may be made without departing from the spirit and scope of the present invention. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

One skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Current Protocols in Molecular Biology (Ausubel et. al., eds. John Wiley & Sons, N.Y. and supplements thereto), Current Protocols in Immunology (Coligan et al., eds., John Wiley St Sons, N.Y. and supplements thereto), Current Protocols in Pharmacology (Enna et al., eds. John Wiley & Sons, N.Y. and supplements thereto) and Remington: The Science and Practice of Pharmacy (Lippincott Williams & Wilicins, 2Vt edition (2005), for example.

Definitions of common terms in molecular biology may be found, for example, in Benjamin Lewin, Genes VII, published by Oxford University Press, 2000 (ISBN 019879276X); Kendrew et al. (eds.); The Encyclopedia of Molecular Biology, published by Blackwell Publishers, 1994 (ISBN 0632021829); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by Wiley, John & Sons, Inc., 1995 (ISBN 0471186341).

For the purpose of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa. In the event that any definition set forth below conflicts with the usage of that word in any other document, including any document incorporated herein by reference, the definition set forth below shall always control for purposes of interpreting this specification and its associated claims unless a contrary meaning is clearly intended (for example in the document where the term is originally used). The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. Furthermore, where the description of one or more embodiments uses the term “comprising,” those skilled in the art would understand that, in some specific instances, the embodiment or embodiments can be alternatively described using the language “consisting essentially of” and/or “consisting of.” As used herein, the term “about” means at most plus or minus 10% of the numerical value of the number with which it is being used.

In some embodiments, a broadly applicable vaccine platform is provided.

In some embodiments, the need for an adjuvant is eliminated. In some embodiments, an adjuvant is not present.

In some embodiments, vaccine safety is improved.

In some embodiments, the manufacture and approval of vaccines is improved or streamlined, or the costs thereof are reduced.

In some embodiments, an adjuvant-independent mucosal vaccine platform is provided, which includes a single recombinant molecule comprising one or more multiple interdependent components, or any combination of: 1) an antigen or antigen-binding component; 2) a component that targets the vaccine antigen to human FcRn; 3) a component that targets the vaccine antigen to human FcγRI; 4) a component that facilitates purification of the vaccine when in protein form. Linker sequences designed to minimize steric interference between adjacent components can connect the individual components. In some embodiments, the components act sequentially and in concert in order to maximize vaccine potency and thereby eliminate the requirement for adjuvant. In some embodiments, the antigen or antigen-binding component provides the immunogen that stimulates protective immunity. In some embodiments, the human FcRn-binding component functions to initially deliver the antigen from the nasal tract to the nasal-associated lymphoid tissue (NALT) via FcRn-containing nasal epithelial cells. In some embodiments, the human FcγRI-binding component will then direct the antigen to human FcγRI-expressing antigen presenting cells within the NALT. In some embodiments, both of the latter events are employed to sufficiently increase vaccine potency to a level that permits the elimination adjuvant. In some embodiments, the human FcRn-binding component will first maximize antigen delivery to the NALT, while the human FcγRI-binding component will subsequently maximize immune stimulation by antigen presenting cells within the NALT. In some embodiments, as a result of this sequence of events, the recombinant vaccine will generate immune protection equal or superior to that of vaccines containing adjuvant.

In some embodiments, the invention provides an immunogenic fusion protein for use as a mucosal vaccine comprising:

-   -   i) one or more FcγR1-binding domains;     -   ii) one or more antigens from one or more infectious disease         organisms; and     -   iii) one or more FcRn-binding domains.

In some embodiments, the invention provides an immunogenic fusion protein for use as a cancer vaccine comprising:

-   -   i) one or more FcγR1-binding domains;     -   ii) one or more antigens from one or more cancers; and     -   iii) one or more FcRn-binding domains.

In some embodiments, the invention provides an immunogenic fusion protein for use as a mucosal vaccine comprising:

-   -   i) one or more FcγR1-binding domains;     -   ii) one or more antigen binding components that bind antigen         from one or more infectious disease organisms; and     -   iii) one or more FcRn-binding domains.

In some embodiments, the invention provides nucleic acids and vectors encoding the immunogenic fusion proteins.

In some embodiments, the vectors can be useful as DNA vaccines. In one embodiment, the invention provides a vector comprising the nucleotide sequence of SEQ ID NO:17 (pUW160s). An antigen or gene of interest can be inserted into SEQ ID NO:17 immediately after nt position 2304. In one embodiment, the invention provides a vector comprising the nucleotide sequence of SEQ ID NO:18 (pJV7563). An antigen or gene of interest can be inserted into SEQ ID NO:18 immediately after nt position 1993.

In some embodiments, the invention provides pharmaceutical compositions comprising the immunogenic fusion proteins.

In some embodiments, the invention provides pharmaceutical compositions comprising the nucleic acids or vectors.

In some embodiments, the invention provides a method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of an immunogenic fusion protein of the invention.

In some embodiments, the invention provides a method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of a nucleic acid encoding an immunogenic fusion protein of the invention.

In some embodiments, the invention provides a method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of nucleic acid encoding any one of the following, or a combination thereof;

i) an immunogenic fusion protein comprising:

-   -   a. one or more antigens from one or more infectious disease         organisms; and     -   b. one or more FcRn-binding domains;

ii) an immunogenic fusion protein comprising:

-   -   a) one or more FcγR1-binding domains; and     -   b) one or more antigens from one or more infectious disease         organisms; and

iii) an immunogenic fusion protein comprising:

-   -   a) one or more FcγR1-binding domains;     -   b) one or more antigens from one or more infectious disease         organisms; and     -   c) one or more FcRn-binding domains.

In some embodiments, the invention provides a method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of a fusion protein of any one of the following, or a combination thereof;

i) an immunogenic fusion protein comprising:

-   -   a) one or more antigens from one or more infectious disease         organisms; and     -   b) one or more FcRn-binding domains;

ii) an immunogenic fusion protein comprising:

-   -   a) one or more FcγR1-binding domains; and     -   b) one or more antigens from one or more infectious disease         organisms; and

iii) an immunogenic fusion protein comprising:

-   -   a) one or more FcγR1-binding domains;     -   b) one or more antigens from one or more infectious disease         organisms; and     -   c) one or more FcRn-binding domains.

In some embodiments, the one or more FcγR1 binding domains is an anti-FcγR1 antibody or a fragment thereof. In some embodiments, the anti-FcγR1 antibody fragment comprises SEQ ID NO:24. In some embodiments, the FcγR1 is human.

In some embodiments, the one or more FcRn binding domains is selected from the group consisting of an anti-FcRn antibody or a fragment thereof and a mammalian serum albumin protein or a fragment thereof. In some embodiments, the FcRn binding domain is human serum albumin or a fragment thereof. In some embodiments, the FcRn binding domain is a fragment of human serum albumin comprising domain III. In some embodiments, the FcRn binding domain is a variant of domain III of human serum albumin having at least 90% amino acid identity. In some embodiments, the fragment of human serum albumin comprising domain III comprises SEQ ID NO: 25. In some embodiments, the FcRn is human.

In some embodiments, the infectious disease organism is a bacterial or viral pathogen. In some embodiments, the pathogen is selected from the group consisting of Streptococcus pneumonia, Neisseria meningitidis, Haemophilus influenza, Klebsiella spp., Pseudomonas spp., Salmonella spp., Shigella spp., and Group B streptococci, Bacillus anthracis adenoviruses; Bordetella pertussus; Botulism; bovine rhinotracheitis; Brucella spp.; Branhamella catarrhalis; canine hepatitis; canine distemper; Chlamydiae; Cholera; coccidiomycosis; cowpox; tularemia; filoviruses; arenaviruses; bunyaviruses; cytomegalovirus; cytomegalovirus; Dengue fever; dengue toxoplasmosis; Diphtheria; encephalitis; Enterotoxigenic Escherichia coli; Epstein Barr virus; equine encephalitis; equine infectious anemia; equine influenza; equine pneumonia; equine rhinovirus; feline leukemia; flavivirus; Burkholderia mallei; Globulin; Haemophilus influenza type b; Haemophilus influenzae; Haemophilus pertussis; Helicobacter pylori; Hemophilus spp.; hepatitis; hepatitis A; hepatitis B; Hepatitis C; herpes viruses; HIV; HIV-1 viruses; HIV-2 viruses; HTLV; Influenza; Japanese encephalitis; Klebsiellae spp. Legionella pneumophila; leishmania; leprosy; lyme disease; malaria immunogen; measles; meningitis; meningococcal; Meningococcal Polysaccharide Group A, Meningococcal Polysaccharide Group C; mumps; Mumps Virus; mycobacteria; Mycobacterium tuberculosis; Neisseria spp; Neisseria gonorrhoeae; ovine blue tongue; ovine encephalitis; papilloma; SARS and associated coronaviruses; parainfluenza; paramyxovirus; paramyxoviruses; Pertussis; Plague; Coxiella bumetti; Pneumococcus spp.; Pneumocystis carinii; Pneumonia; Poliovirus; Proteus species; Pseudomonas aeruginosa; rabies; respiratory syncytial virus; rotavirus; Rubella; Salmonellae; schistosomiasis; Shigellae; simian immunodeficiency virus; Smallpox; Staphylococcus aureus; Staphylococcus spp.; Streptococcus pyogenes; Streptococcus spp.; swine influenza; tetanus; Treponema pallidum; Typhoid; Vaccinia; varicella-zoster virus; and Vibrio cholera and combinations thereof.

The antigen from the pathogen is not limiting. In some embodiments, the antigen is selected from the group consisting of: PspA (Streptococcus pneumonia), gp120 (HIV), hemagglutinin (influenza) and neuraminidase (influenza). In some embodiments, the antigen is PspA. The nucleotide sequence of PspA is provided in SEQ ID NO:16.

The one or more antigen binding components that bind antigen from one or more infectious disease organisms is not limiting. In some embodiments, the one or more antigen binding components comprises C reactive protein (CRP) (HGNC: 2367) or a fragment thereof, C3 (HGNC: 1318) or a fragment thereof, myelin basic protein (MBP) (HGNC: 6925) or a fragment thereof, CD6 (HGNC: 1691) or a fragment thereof, CD163 (HGNC: 1631) or a fragment thereof, and combinations thereof.

The one or more antigens from one or more cancers is not limiting. In some embodiments, the one or more antigens from one or more cancers is selected from the group consisting of wherein the antigen is selected from the group consisting of hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBcAg), and hepatitis B e antigen (HBeAg), N53, NS4a, NS5a and NS5b, HPV E6/E7, EBV LMP, HBV, HCV, mutated k-ras, p53, bcr-abl, HER-2, hTERT, ganglioside GD3, NY-ESO-1, MAGE/BAGE/GAGE, Hu, Yo, GAD, MART-1/melan-A, gp-100, tyrosinase, PSA and combinations thereof.

The cancer to be treated is not limiting and can include acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical cancer, AIDS-related cancers, AIDS-related lymphoma, anal cancer, astrocytoma (including, for example, cerebellar and cerebral), basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor (including, for example, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal, visual pathway and hypothalamic glioma), cerebral astrocytoma/malignant glioma, breast cancer, bronchial adenomas/carcinoids, Burkitt's lymphoma, carcinoid tumor (including, for example, gastrointestinal), carcinoma of unknown primary site, central nervous system lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, cutaneous T-Cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing's Family of tumors, extrahepatic bile duct cancer, eye cancer (including, for example, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor (including, for example, extracranial, extragonadal, ovarian), gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, squamous cell head and neck cancer, hepatocellular cancer, Hodgkin's lymphoma, hypopharyngeal cancer, islet cell carcinoma (including, for example, endocrine pancreas), Kaposi's sarcoma, laryngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, lung cancer (including, for example, non-small cell), lymphoma, macroglobulinemia, malignant fibrous histiocytoma of bone/osteosarcoma, medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, mouth cancer, multiple endocrine neoplasia syndrome, multiple myeloma!plasma cell neoplasm, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases, myeloma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, oral cancer, oral cavity cancer, osteosarcoma, oropharyngeal cancer, ovarian cancer (including, for example, ovarian epithelial cancer, germ cell tumor), ovarian low malignant potential tumor, pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, pregnancy and breast cancer, primary central nervous system lymphoma, prostate cancer, rectal cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, soft tissue sarcoma, uterine sarcoma, Sézary syndrome, skin cancer (including, for example, nonmelanoma or melanoma), small intestine cancer, supratentorial primitive neuroectodermal tumors, T-Cell lymphoma, testicular cancer, throat cancer, thymoma, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, trophoblastic tumor (including, for example, gestational), unusual cancers of childhood and adulthood, urethral cancer, endometrial uterine cancer, uterine sarcoma, vaginal cancer, viral induced cancers (including, for example, HPV induced cancer), vulvar cancer, Waldenström's macroglobulinemia, and Wilms' Tumor.

In some embodiments, the immunogenic fusion protein enhances transepithelial transport of the fusion protein to the nasal-associated lymphoid tissue (NALT) and enhances FcγR1 crosslinking by the fusion protein on antigen presenting cells (APC) within the NALT.

In some embodiments, the fusion protein comprises two or more FcγR1 binding domains. In some embodiments, the fusion protein comprises three FcγR1 binding domains.

In some embodiments, the immunogenic fusion protein comprises bivalent Anti-FcγRI-PspA-HuSA. In some embodiments, the bivalent Anti-FcγRI-PspA-HuSA comprises the amino acid sequence of SEQ ID NO:12. In some embodiments, the bivalent Anti-FcγRI-PspA-HuSA comprises the nucleotide sequence of SEQ ID NO:23.

In some embodiments, the immunogenic fusion protein comprises trivalent Anti-FcγRI-PspA-HuSA. In some embodiments, the trivalent Anti-FcgRI-PspA-HuSA comprises SEQ ID NO:13. In some embodiments, the trivalent Anti-FcγRI-PspA-HuSA comprises the nucleotide sequence of SEQ ID NO:20.

In some embodiments, the immunogenic fusion protein comprises a cleavable protein sequence and/or affinity tag to aid in purification. In some embodiments, the affinity tag comprises at least 6 histidine residues. In some embodiments, the immunogenic fusion protein comprises a secretion signal to facilitate secretion of the protein through plasma membrane. In some embodiments, the secretion signal is a lysozyme secretion signal.

In some embodiments, wherein upon administration to a subject, the fusion protein generates protection against both mucosal and non-mucosal pathogens. In some embodiments, the fusion protein generates protection at mucosal and non-mucosal sites.

In some embodiments, the vaccine platform includes a recombinant molecule containing single or multiple antigens from a single infectious disease organism.

In some embodiments, the vaccine platform includes a recombinant molecule containing single or multiple antigens from multiple infectious disease organisms.

In some embodiments, the one or more antigen binding components includes a component that binds to live attenuated infectious disease organisms.

In some embodiments, the one or more antigen binding components includes a component that binds to inactivated infectious disease organisms.

In some embodiments, the vaccine platform includes an antigen from cancerous or tumor cells.

In some embodiments, the vaccine platform includes a single or multiple human FcRn-binding domains.

In some embodiments, the vaccine platform includes a single or multiple human FcγRI-binding domains.

In some embodiments, the vaccine platform includes a cleavable protein purification component.

In some embodiments, the vaccine platform includes an additional immune modulatory component.

In some embodiments, the additional immune modulatory component is or includes a TLR agonist, Complement component, or cytokine analogue.

In some embodiments, the vaccine platform includes a DNA or RNA vaccine administered intradermally or intranasally.

In some embodiments, the vaccine platform includes a DNA or RNA vaccine, which lacks the FcRn-binding component when administered intradermally.

In some embodiments, the vaccine platform includes a immunogenic fusion protein which lacks the FcRn-binding component.

In some embodiments, trivalent Anti-FcγRI-PspA can be utilized in the invention, which lacks a FcRn-binding component. In some embodiments, the amino acid sequence of trivalent Anti-FcγRI-PspA is SEQ ID NO:11 and the nucleotide sequence is SEQ ID NO:19.

In some embodiments, bivalent Anti-FcγRI-PspA can be utilized in the invention, which lacks a FcRn-binding component. In some embodiments, the amino acid sequence of bivalent Anti-FcγRI-PspA is SEQ ID NO:12 and the nucleotide sequence is SEQ ID NO:21.

In some embodiments, the vaccine platform includes a DNA or RNA vaccine, which induces secretion of the recombinant protein vaccine into the nasal tract, when administered intranasally.

In some embodiments, the vaccine platform includes a protein vaccine administered intradermally or intranasally.

In some embodiments, the vaccine platform includes a protein vaccine, which lacks the FcRn-binding component, when administered intradermally. In some embodiments, Non-FcγRI targeted PspA-HuSA can be useful. In some embodiments, the amino acid sequence of PspA-HuSA is SEQ ID NO:14 and the nucleotide sequence is SEQ ID NO:22.

In some embodiments, the vaccine platform is administered as a DNA vaccine intradermally and subsequently a protein vaccine intranasally.

In some embodiments, the vaccine platform is administered as a protein vaccine intradermally and subsequently a DNA vaccine intranasally.

In some embodiments, the vaccine platform generates protection against both mucosal and non-mucosal pathogens.

In some embodiments, the vaccine platform generates protection at mucosal and non-mucosal sites.

In some embodiments, the vaccine platform includes a single vaccine containing a population of recombinant vaccine molecules, each containing a different infectious disease antigen or a set of infectious disease antigens.

In some embodiments, the vaccine platform includes a single vaccine containing a population of recombinant molecules, each containing a different tumor antigen or a set of tumor antigens.

In some embodiments, the vaccine platform is humanized. In some embodiments, the vaccine platform is modified to eliminate autoreactive and/or antigenic sequences unrelated to the infectious disease or tumor antigen(s).

In some embodiments, a fusion protein comprising Streptococcus pneumonia antigen PspA is provided. In some embodiments, a divalent anti-hFcγRI-PspA-HSA (human serum albumin fragment) FP is provided. In some embodiments, a trivalent anti-hFcγRI-PspA-HSA FP is provided.

In some embodiments, the divalent and trivalent anti-hFcγRI-PspA-HSA FP is functional in vivo based on FcR binding (hFcγRI, FcRn), enhanced FP internalization via hFcγRI, enhanced transepithelial transport of Ag via FcRn, and enhanced hFcγRI-mediated presentation of PspA to PspA-specific T cells.

In some embodiments, PspA, anti-hFcγRI-PspA, and anti-hFcγRI-PspA-HSA containing DNA vaccine vectors are provided.

In some embodiments, a formulation (bi- vs. trivalent FP; FcRn vs. non-FcRn-binding; DNA, FP, or DNA prime-FP boost), route (i.n., i.d., or i.m.), and dose, is provided based on Streptococcus pneumonia immunogenicity and protection.

In some embodiments, the Streptococcus pneumonia vaccine platform affords broad protection against 2 or more strains of Streptococcus.

In some embodiments, immunogenicity and protection is comparable or superior to the vaccines such as Prevnar®13.

In some embodiments, the flu HA FP induces broad protection against homologous and drifted strains of flu.

In some embodiments, immunogenicity and protection is comparable or superior to vaccines such as Fluzone.

The present invention further provides pharmaceutical compositions comprising the fusion proteins and nucleic acids in combination with a pharmaceutically acceptable excipient.

In one embodiment, pharmaceutically acceptable means a material that is compatible with the other ingredients of the composition without rendering the composition unsuitable for its intended purpose, and is suitable for use with subjects as provided herein without undue adverse side effects (such as toxicity, irritation, and allergic response). Side effects are “undue” when their risk outweighs the benefit provided by the composition. Non-limiting examples of pharmaceutically acceptable carriers or exipients include, without limitation, any of the standard pharmaceutical carriers or excipients such as phosphate buffered saline solutions, water, emulsions such as oil/water emulsions, microemulsions, and the like.

The fusion proteins and nucleic acids described herein can be prepared and/or formulated without undue experimentation for administration to a mammal, including humans, as appropriate for the particular application. The pharmaceutical compositions may be manufactured without undue experimentation in a manner that is itself known, e.g., by means of conventional mixing, dissolving, dragee-making, levitating, emulsifying, encapsulating, entrapping, spray-drying, or lyophilizing processes, or any combination thereof.

Suitable routes of administration may include, for example, oral, lingual, sublingual, rectal, transmucosal, nasal, buccal, intrabuccal, intravaginal, or intestinal administration; intravesicular; intraurethral; topical administration; transdermal administration; administration by inhalation; parenteral delivery, non-parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, and optionally in a depot or sustained release formulation. Furthermore, one may administer the compound in a targeted drug delivery system, for example in a liposome. Combinations of administrative routes are possible.

Proper dosages of the fusion proteins can be determined without undue experimentation using standard dose-response protocols. In one embodiment, the dosage of the compound, salt thereof, or a combination thereof, or pharmaceutical composition, may vary from about 0.001 μg/kg to about 1000 mg/kg. This includes all values and subranges therebetween, including 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1 μg/kg , 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 75, 100, 200, 300, 400, 500, 600, 700, 800, 900, and 1000 mg/kg, and any combination thereof.

In one embodiment, the fusion proteins and/or nucleic acids are administered mucosally.

The fusion proteins and nucleic acids can also be prepared for nasal administration. As used herein, nasal administration includes administering the compound to the mucous membranes of the nasal passage or nasal cavity of the subject. Pharmaceutical compositions for nasal administration of the compound include therapeutically effective amounts of the compound prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. Administration of the compound may also take place using a nasal tampon or nasal sponge.

The compositions may also suitably include one or more preservatives, anti-oxidants, or the like.

Some examples of techniques for the formulation and administration of the fusion proteins and nucleic acids may be found in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins Publishing Co., 20 addition, incorporated herein by reference.

In one embodiment, the pharmaceutical compositions contain the fusion protein or nucleic acid in an effective amount to achieve their intended purpose. In one embodiment, an effective amount means an amount sufficient to prevent or treat the disease. In one embodiment, to treat means to reduce the development of, inhibit the progression of, or ameliorate the symptoms of a disease in the subject being treated. In one embodiment, to prevent means to administer prophylactically, e.g., in the case wherein in the opinion of the attending physician the subject's background, heredity, environment, occupational history, or the like, give rise to an expectation or increased probability that that subject is at risk of having the disease, even though at the time of diagnosis or administration that subject either does not yet have the disease or is asymptomatic of the disease.

While the invention has been described with reference to certain particular examples and embodiments herein, those skilled in the art will appreciate that various examples and embodiments can be combined for the purpose of complying with all relevant patent laws (e.g., methods described in specific examples can be used to describe particular aspects of the invention and its operation even though such are not explicitly set forth in reference thereto).

Other embodiments of the invention are discussed throughout this application. Any embodiment discussed with respect to one aspect applies to other aspects as well and vice versa. Each embodiment described herein is understood to be embodiments that are applicable to all aspects of the invention. It is contemplated that any embodiment discussed herein can be implemented with respect to any device, method, or composition, and vice versa. Furthermore, systems, compositions, and kits of the invention can be used to achieve methods of the invention.

Aspects of the present teachings may be further understood in light of the following examples, which should not be construed as limiting the scope of the present teachings in any way.

EXAMPLES

A highly potent mucosal vaccine platform, which does not require adjuvant, can be generated utilizing a human FcγRI (hFcγRI)-specific-antigen (Ag) fusion protein (FP), which: 1) Incorporates a human FcRn (hFcRn)-binding sequence to increase transepithelial transport of FP to the nasal-associated lymphoid tissue (NALT). 2) Has increased valency in its hFcγRI-targeting component to further enhance Ag internalization, Ag processing, dendritic cell (DC) maturation, and Ag presentation in the NALT. 3) Combines an i.n. hFcR-targeted DNA vaccine-prime with an i.n. FP-boost to maximize and sustain vaccine potency.

The mucosa is the first line of defense against many pulmonary bacterial and viral pathogens and their antigenic variants. Also, mucosal immunity, induced by natural infection or vaccination, can afford better protection than peripheral immune responses, including improved cross-protection against antigenic variants¹⁻⁴. Without wishing to be bound by theory, it is believed that this is likely due, in part, to a crucial early opportunity to prevent a disseminated infection by eliminating/blocking the infection at its most vulnerable stage, while the infection is still limited. However, most licensed vaccines induce responses primarily in the periphery, producing a suboptimal immune response at the initial mucosal site of exposure. In addition, the most commonly used vaccine platforms—live attenuated and adjuvanted protein vaccines—often cause adverse inflammatory effects when administered via a mucosal route. Unadjuvanted protein vaccines are safer, but usually poorly immunogenic. Thus, we propose the development of a novel and highly potent mucosal FP vaccine platform, which does not require the use of adjuvant. The FP will: 1) Target Ag to hFcRn to increase Ag transepithelial transport to the NALT⁵. 2) Increase hFcγRI crosslinking on APCs within the NALT to enhance Ag presentation and T cell activation⁶⁻¹⁰. 3) Combine an i.n. administered hFcR-targeted DNA vaccine-prime with an i.n. FP-boost. A strategy that has been shown to enhance the magnitude, quality, and longevity of protein vaccines¹¹. Data, which support the successful development of the proposed adjuvant-independent mucosal vaccine platform include the use of a hFcγRI transgenic mouse model in which pneumococcal surface protein A (PspA) targeted to hFcγRI i.n. generates enhanced mucosal immunity and protection against a mucosal challenge with Streptococcus pneumoniae (Sp), without the use of adjuvant ⁷ . We have also shown that a mAb-bound inactivated Francisella tularensis (mAb-iFt) complex administered i.n. enhances protection against mucosal Ft challenge. This protection is FcγR-dependent and requires FcRn ⁸ . Subsequent studies have also demonstrated that FcRn mediates enhanced transport of mAb-iFt versus iFt alone from the nasal passage to the NALT ⁹ . Thus, a strong potential for the successful development of the proposed adjuvant-free mucosal vaccine platform has been demonstrated using two distinct FcR-targeted vaccine strategies and two distinct mucosal infectious disease models in which enhanced protection has been observed without the use of traditional adjuvant. A novel/unique FP will now be generated/developed to maximize adjuvant-free FP potency, which will be crucial to its successful application, as well as altering long established perceptions regarding the requirement for adjuvant. Specifically, we will incorporate molecular modifications to our bivalent prototype FP to further improve FP targeting and immunogenicity: 1) A sequence, which targets FPs to hFcRn ^(12,13) , will be added to increase FP delivery to the NALT. 2) The divalent anti-hFcγRI-PspA FP will be converted to a trivalent hFcγRI-targeted FP to further enhance Ag internalization, Ag processing, DC maturation, and subsequent Ag presentation^(9,10,14,15) within the NALT. 3) An i.n. administered hFcR-targeted DNA vaccine-prime will be combined with an i.n. FP-boost to further improve vaccine potency and durability ¹⁶⁻²⁰ .

Aim 1: Produce and verify in vitro, the functional capacity of bivalent, trivalent, and hFcRn-targeted anti-hFcγRI-PspA FPs. The bivalent, trivalent, and hFcRn-targeted anti-hFcγRI-PspA FPs have been produced. FP functions tested will include: hFcRn binding and transepithelial transport of FPs, FP binding to hFcγRI, FP internalization by APCs, and the ability of FPs to induce DC maturation and FP-enhanced Ag presentation/T cell activation.

Aim 2: Identify the optimal (most protective) FP configuration utilizing a hFcγRI/hFcRn-expressing mouse model. Bivalent versus trivalent hFcRI-targeted FPs (plus or minus the hFcRn binding component) will be administered i.n. at varying FP doses. Protection against Sp challenge and PspA-specific T and B cell responses will be measured. The optimal FP will be identified based primarily on superior protection provided.

Aim 3: Maximize FP vaccine platform potency and protective longevity utilizing an i.n. administered hFcR-targeted DNA vaccine-prime plus i.n. FP-boost regimen. The ability of FP, hFcR-targeted DNA, and hFcR-targeted DNA vaccine-prime plus FP-boost regimens, each administered i.n., to further enhance protection and extend immune memory, without the use of adjuvant, will be tested. The optimal Sp vaccine regimen will then be compared to licensed Sp vaccine, followed by cross-protection studies to validate the cross-protective potential of this vaccine platform, in particular as it applies to Sp vaccination.

Current approaches to vaccine development are as diverse as the infectious organisms they are designed to protect against. However, most current protein-based vaccine strategies require two primary components: identification of a protective antigen (Ag) and the use of an appropriate adjuvant. Adjuvants can be divided into two primary categories: immune modulators and delivery systems²¹. Immune modulators include: bacterial products [lipopolysaccharides, peptidolglycans, lipoproteins, DNA (CpGs), and enterotoxins], plant products (saponins and glycosylceramides), and cell products (heat shock proteins and cytokines). Mechanisms of action include: dendritic cell (DC)/macrophage activation, up-regulation of costimulatory molecules (required for efficient T cell activation), and induction of cytokines involved in immune regulation. However, most immune modulators have broad specificity and activity, increasing potential toxic side effects and raising safety concerns. Vaccine delivery systems are more limited in number. Delivery systems function primarily by slowing Ag release at the site of injection and/or enhancing Ag uptake by Ag presenting cells (APCs). The only delivery system currently approved for human use in the U.S. is mineral salt, specifically Alum, which induces a potent antibody (Ab) (humoral, Th2-type) response, but is ineffective at boosting cellular (Th1-type or CD8 T cell) responses. Another delivery system consists of emulsions (Ag mixed with oil and water) such as MF59. However, similar to mineral salt (Alum), MF59 stimulates a potent humoral (Th2-type) immune response, but fails to stimulate cellular immune responses. A third delivery system consists of particulate Ag, such as the incorporation of Ag into lipid-containing vesicles or nanoparticles. Particulate Ag can stimulate both humoral and cellular immune responses. However, manufacture and maintenance of particle consistency can be difficult and expensive, potentially resulting in a vaccine product, which 3^(rd) world countries cannot afford. In addition, the adjuvants discussed above are generally used in parenteral immunizations, which often do not produce strong mucosal immunity²². Yet, the majority of pathogens enter via mucosal routes. In contrast, mucosal immunization can provide potent protection at both mucosal and non-mucosal sites⁵. Furthermore, as specifically pointed out in a number of reviews, including in Nature Medicine and Nature Reviews, this applies to human vaccination, as well as that of mice²³⁻²⁵. Thus, there is a need for more effective and safe mucosal vaccination strategies and/or mucosal adjuvants. While both Cholera Toxin B (CTB) and IL-12 can be effective as mucosal adjuvants in mice²⁶⁻²⁸, and possibly humans, as with many adjuvants, there is significant concern regarding their toxicity/safety. Therefore, a mucosal vaccine platform, which does not require adjuvant and can stimulate both humoral and cellular immune responses, such as the use of FcR-targeted mucosal immunogens [anti-FcR fusion proteins (FPs)]^(5,29), would significantly advance vaccine technology, while eliminating many of the issues associated with the use of adjuvants. As stated by Dr. Jerry McGhee, a world renown mucosal immunologist, “The development of effective strategies for mucosal vaccination would revolutionize medicine”⁵. In addition, targeting Ag to hFcγRI bypasses the inhibitory receptor FcγRIIB, which can limit FcγR-induced DC maturation and Ab production^(14,15). Accordingly, we propose the development of a highly innovative adjuvant-independent (recombinant) mucosal vaccine platform, which sequentially targets FP Ag to: 1) hFcRn for enhanced transepithelial transport of Ag to the nasal-associated lymphoid tissue (NALT), and 2) hFcγRI on APCs/DCs for enhanced Ag processing/presentation and T cell/B cell activation within the NALT (FIG. 1). In addition, we will combine a hFcR-targeted DNA vaccine-prime with an i.n. FP-boost to further optimize vaccine potency and durability¹⁶⁻²⁰.

The current paradigm for vaccine development involves the identification of a protective Ag and the requirement for a safe and effective adjuvant. Given the myriad of problems adjuvants face, including safety concerns and FDA approval, and the paucity of researchers challenging this paradigm by developing adjuvant-free vaccine strategies, the proposed adjuvant-free FP platform is a highly innovative approach to mucosal vaccine development. Furthermore, the creation of a unique/novel dual (hFcγRI/hFcRn)-targeted multi-functional FP, which mediates sequential targeting of FP Ag to hFcRn i.n. for enhanced transepithelial transport of FP Ag to the NALT and subsequently FP Ag to hFcγRI on APCs for enhanced T and B cell activation within the NALT (FIG. 1), is also highly innovative. Lastly, these will represent the first studies that seek to combine a hFcR-targeted DNA vaccine and hFcR-targeted mucosal FP vaccine in a DNA-prime FP-boost regimen.

Regarding the potential for developing an adjuvant-free mucosal vaccine, published studies and preliminary data validate the potential for success of the proposed FP-based mucosal vaccine platform. Specifically, partial protection against the highly virulent F. tularensis (Ft) SchuS4 organism is achieved when immunizing i.n. with adjuvant-free inactivated Ft (iFt) targeted to FcR via mAb-iFt complex ⁸ . Furthermore, these studies demonstrate important roles for FcγR and FcRn in this protection. Specifically, mice immunized i.n. with mAb-iFt are not protected in the absence of FcγR or FcRn ⁸ . Also, subsequent mechanistic studies indicate that FcRn plays a critical role in enhancing the transport of iFt to the NALT, when immunizing i.n. with mAb-iFt ⁹ . Importantly, the enhanced transport of iFt to the NALT is eliminated in the absence of FcRn. In addition, subsequent studies by other laboratories have demonstrated a similar function for FcRn, when utilizing i.n. administered recombinant Fc-Ag immunogens plus adjuvant ^(30,31). In 2012, one of the present inventors also published studies utilizing a hFcγRI transgenic (Tg) mouse model and a prototype bivalent [mono (hFcγRI)-specific] anti-hFcγRI-PspA FP. These studies demonstrated that administering this prototype anti-hFcγRI-PspA FP i.n. to hFcγRI Tg mice in the absence of adjuvant enhances protection against subsequent S. pneumoniae (Sp) challenge (FIG. 2)⁷. Importantly, the enhanced protection observed requires both the presence of hFcγRI in vivo and PspA targeted to hFcγRI in the form of anti-hFcγRI-PspA FP⁷. Sp-specific IgA and IgG responses (FIG. 3), Ab-dependent complement deposition on Sp, and lactoferrin-mediated killing of Sp, are also enhanced⁷. The above enhancement is not observed in non-hFcγRI Tg [wildtype (WT)] mice⁷. Furthermore, while FcRn targeting is not required in the case of bivalent anti-hFcγRI-PspA FP, possibly due to M cell-mediated transport of FP, an FP that sequentially targets Ag to FcRn for transepithelial transport of FP to the NALT, and subsequently to multiple hFcγRIs for enhanced hFcγRI crosslinking on APCs/DCs within the NALT (FIG. 1), is very likely to significantly improve the potency, and thus efficacy, of the adjuvant-independent hFcR-targeted FP vaccine platform.

The FP DNA constructs to be used in these studies, which have been generated, are depicted in FIG. 4. The trivalent anti-hFcγRI-PspA and divalent anti-hFcγRI-PspA-HSA FPs have also been produced and bind hFcγRI and hFcγRI/hFcRn, respectively (FIG. 5). Thus, the ability to generate functional divalent and trivalent FPs, as well as FPs that bind both hFcRn and hFcγRI, is demonstrated (FIG. 5). Furthermore, in Aim 3, we also provide preliminary studies demonstrating the efficacy of i.n. DNA vaccination with hFcγRI-targeted immunogen.

Development of vaccine platform technology such as that proposed, which eliminates the requirement for adjuvant, will fundamentally alter the paradigm by which vaccines are generated and administered. In addition, as stated by Dr. McGhee⁵ “The development of effective strategies for mucosal vaccination would revolutionize medicine, allowing protection from the many viral and bacterial pathogens that enter the body via the mucosa . . . ”^(5,30,31). Specifically, the proposed FP platform will be the first recombinant unadjuvanted mucosal vaccine platform to take full advantage of this “Mucosal Gateway” for vaccination (FIG. 1) by facilitating the sequential transepithelial transport of FP Ag from the nasal passage to the NALT (via FcRn), and subsequently targeting FP Ag to hFcγRI on APCs within the NALT, while maximizing hFcγRI crosslinking on APCs in the NALT. Furthermore, development of this FP mucosal vaccine platform technology will fundamentally transform the generation and administration of vaccines against a wide array of infectious agents including: emerging, re-emerging, and biodefense pathogens, as well as non-mucosal pathogens. Finally, development of a vaccine platform that does not require adjuvant will significantly reduce safety concerns and concerns related to the limited capacity of many adjuvants to stimulate both humoral and cellular immunity.

Aim 1: Produce and verify in vitro, the functional capacity of bivalent, trivalent, and FcRn-targeted anti-hFcγRI-PspA FPs.

Published studies by one of the inventors demonstrate that a prototype bivalent anti-hFcγRI-PspA FP administered i.n. to hFcγRI Tg mice, enhances protection against subsequent i.n. challenge with Sp in the absence of adjuvant⁷. Others, when targeting Ag to FcRn i.n., but with adjuvant, have obtained similar results^(30,31). Evidence suggests that the above FcRn-mediated enhancement is due, in part, to increased transport of Ag from the nasal passage to the underlying NALT^(5,31). Thus, to further optimize the potency of our current prototype divalent anti-hFcγRI-PspA FP, a sequence from human serum albumin (HSA-Domain III), which binds FcRn and mediates FcRn-dependent transepithelial transport of Ags¹³, has been added to the divalent anti-hFcγRI-PspA FP. We have also converted the bivalent FP to a trivalent FP to more extensively cros slink hFcγRI on APCs, thereby enhancing Ag internalization, DC maturation^(9,10,14,15), Ag presentation/T cell activation, and ultimately vaccine potency. In regard to the use of a bivalent versus trivalent FP, it has been clearly demonstrated that anti-hFcγRI-targeted Ags are significantly more potent immunogens in trivalent vs. divalent form^(6,10). Furthermore, maximizing FP potency will be crucial to establishing a new paradigm in which the use of this adjuvant-free mucosal vaccine platform is a viable and an acceptable alternative to adjuvant.

Objectives: 1) Generate DNA constructs and produce FPs; 2) Verify FP function(s) in vitro.

Aim 1.1: Generation of DNA constructs and production of FPs.

FP DNA constructs depicted in FIG. 4, including control PspA and PspA-HSA constructs, have been generated. Functional bivalent and trivalent anti-hFcγRI-PspA and bivalent anti-hFcγRI-PspA-HSA FPs have also been produced (FIG. 5). Clones representing good producers of each construct will be expanded into a FiberCell system for producing concentrated FP supernatant and FPs will be purified by Nickel column. The successful isolation/purification of FPs will be verified by Western blot analysis and ELISA, as previously described.

Aim 1.2: Verification of FP function in vitro.

FP binding to hFcγRI and hFcRn: Binding of hFcγRI-specific FPs to hFcγRI and HSA-containing FPs to hFcRn will be measured by ELISA (FIG. 5) and confirmed via flow cytometry, using hFcγRI or hFcRn-expressing cells/DCs, as previously described ⁷ . However, in the case of ELISAs measuring FP binding to FcRn, wells will be coated with soluble hFcRn and the ELISA carried out at the appropriate pH (6.0), which is required for FcRn to bind HSA (FIG. 5B). Analogous FPs lacking HSA will serve as negative controls in the latter case (FIGS. 4 and 5B). To monitor hFcγRI and/or FcRn binding by flow cytometry, bone marrow-derived DCs (BMDCs) from hFcRn and/or hFcγRI-expressing mice will be used. BMDCs will be obtained as previously described by Dr. Gosselin ⁷ . In the case of hFcγRI binding, incubations and washes will be carried out at 4° C. FP binding will be detected by incubation with Rb anti-PspA or Rb anti-HSA Ab followed by three washes and subsequent addition of FITC labeled goat anti-Rb IgG. Cells will then be fixed and analyzed by flow cytometry. FcRn binding of FPs to DCs will be carried out similar to that of hFcγRI, but in a manner that detects intracellular binding, as previously published by others ³² . BMDCs from non-hFcγRI/FcRn-expressing mice will serve as negative controls.

Transepithelial transport of HSA-containing (FcRn-targeted) FPs: Modification of a standard in vitro IgG transport assay ³³ will be used to assess HSA-containing FPs versus FPs lacking HSA to interact with FcRn from human epithelial cells and subsequently transit an epithelial layer. Briefly, T84 cells expressing human FcRn will be grown on transwell filter inserts to form a monolayer exhibiting transepithelial electrical resistance (300 ohms/cm2) as measured via a tissue-resistance meter equipped with planar electrodes. In addition to electrical resistance, confocal microscopy, immunohistochemistry, and bulk protein transport, will also be used to verify monolayer integrity ^(32,34) . Monolayers will be equilibrated in Hanks balanced salt solution. FPs will be applied to the apical compartment, and incubated with DMEM medium plus or minus competitor for FcRn (Free HSA) at varying concentrations for 1-4 hours at 37° C. Time point samples taken from the basolateral compartment will then be assayed for FPs via Western blot or ELISA. IgG will also be used as a positive control for FcRn-mediated transepithelial transport. Once, transepithelial transport has been verified using T84 cells, similar assays will be conducted using tracheal epithelial cells from WT, hFcRn Tg, hFcγRI Tg, and hFcγRI/hFcRn Tg mice.

Induction of DC maturation by FPs: Bivalent and trivalent FPs will be incubated with BMDCs and DC maturation measured by monitoring maturation markers (MHC Class II, CD40, CD80, CD86, and CD205) by flow cytometry, as previously described ⁹ .

FP-mediated PspA presentation to PspA-specific T cells: This assay will also be conducted as previously described ⁷ . Briefly, the PspA-specific T cell hybridoma (B6D2) (1×10⁵ cells/well) will be co-cultured with hFcγRI/FcRn-expressing, non-hFcRn-expressing, and/or non-hFcγRI-expressing BMDCs (2×10⁵ cells/well) with titrating amounts of PspA or PspA-containing FPs. Equivalent PspA concentrations will be used as the basis for equilibrating FP concentrations and thereby comparing presentation of the various FPs, with concentrations ranging from 0 to 10 μg/ml of PspA. Cells will then be incubated for 30 hours at 37° C. in 5% CO₂, supernatants will be collected, and IL-2 production will be measured via Luminex assay. In addition to BMDCs from non-hFcγRI/FcRn-expressing mice, wells lacking BMDCs or FP Ag will also serve as negative controls, as well as wells containing soluble F(ab′)₂ anti-hFcRn and/or anti-hFcγRI blocking mAbs, to further confirm hFcγRI and/or FcRn involvement.

Potential outcomes and alternative approaches: Bivalent and trivalent FPs, as well as anti-FcγRI-PspA-HSA FP have been produced and bind both hFcRn and/or hFcγRI (FIG. 5). Also, as indicated in FIG. 5 and a recent publication⁷, the present inventors have extensive experience producing FcR-targeted FPs. Problems could however occur with the trivalent anti-hFcγRI-PspA-HSA FP. Trivalent FP binding to hFcγRI could be reduced compared to bivalent FP, possibly due to the presence of the trivalent component itself and/or the HSA component. However, this would not necessarily mean diminished vaccine function. Specifically, it is believed that the trivalent FP is more likely to form more stable (higher avidity) bonds with hFcγRI and engage more hFcγRI molecules per FP than bivalent FP, producing a lower signal by ELISA and flow cytometry. Yet, these same changes could also result in an FP, which more extensively cross-links hFcγRI on APCs^(6,10), thereby inducing enhanced DC maturation, PspA internalization, and PspA presentation/T cell activation. Thus, judgment of trivalent FP function will be based on results of hFcγRI-binding and Ag presentation assays. If the trivalent FP still underperforms versus bivalent FP, linkers can be lengthened, in one embodiment, separating V_(L)-V_(H) segments to reduce interdomain interference, thereby potentially increasing flexibility of the hFcγRI-binding domains. In another embodiment, the divalent FP may be combined with the FcRn-targeting component (HSA), and subsequently, a DNA-prime protein-boost regimen (Aim 3). One possible issue, in regard to in vivo use of FcRn-binding FPs, is the presence of low levels of serum albumin in the nasal tract. The latter could compete with the HSA-containing FPs for binding to FcRn. Indeed, due to the fact the albumin levels are relatively low in the nasal tract, albumin is often used to measure epithelial integrity^(35,36). Thus, while it is not believed that this will be a serious problem due in particular to the low albumin levels [<6 μg/ml in nasal lavage³⁶], we will titrate in free HSA in the presence of FPs in the in vitro ELISA binding and epithelial transport assays to determine what levels of free serum albumin fully compete with FP binding to FcRn. Should the level be equal to or less than that normally found in the nasal tract, we will first verify this inhibition in vivo, then consider the use of alternative FcRn binding components such as Fc sequences to replace HSA. Should it ultimately not be possible to overcome this issue, one option is to focus on the divalent and/or trivalent FP lacking the FcRn-binding component and combining the bivalent and/or trivalent hFcγRI-targeted FP with a DNA-prime protein-boost regimen (Aim 3) to further enhance FP vaccine efficacy.

Aim 2: Optimize FP platform immunogenicity and protective efficacy utilizing the FPs generated and tested in Aim 1 and a hFcγRI/hFcRn-expressing mouse model.

It will be critical to first identify the FP generated in Aim 1, which is most protective against Sp challenge. Thus, we will compare the protective capacity of bivalent vs. trivalent FPs (plus and minus FcRn-binding HSA) using a hFcγRI/FcRn-expressing mouse model. Once the optimal (most protective) FP formulation is identified, the optimal dose will be determined, and humoral and cellular immune responses to FP vaccination will also be examined While mucosal and parenteral immunization routes have proven successful in the case of Sp vaccines, mucosal routes are generally believed to be superior for mucosal pathogens in mouse and humans²³⁻²⁵. Thus, we will focus on the i.n. immunization route.

Objectives: 1) Utilizing a hFcγRI/FcRn-expres sing mouse model, identify the FP formulation providing optimal protection against Sp challenge; 2) Using the above optimal FP formulation, identify the optimal FP dose that provides maximal protection in this challenge model; 3) Examine humoral and cellular immune responses to the FP vaccine.

Aim 2.1: Determine which FP provides optimal protection against Sp challenge utilizing a hFcRI/FcRn-expressing mouse Sp protection model.

We currently maintain a colony of hFcγRI Tg and non-Tg littermate mice by breeding one male C57BL/6 hFcγRI Tg+/− mouse with two female C57BL/6 WT mice per breeding colony. The hFcγRI Tg mice are then identified by PCR. To generate hFcγRI/FcRn-expressing mice, we will similarly breed a male hFcγRI Tg+/− mouse with two C57BL/6 hFcRn (+/+) mice (Jackson Laboratories). Mice expressing both hFcγRI and hFcRn will again be identified by PCR, as is done to verify the presence of hFcγRI. Mice will be divided into groups of 8 mice/group, 8-12 weeks of age. Human FcγRI/FcRn-expressing mice will be immunized i.n. with 20 μl of PBS, PspA, PspA-HSA, bivalent anti-hFcγRI-PspA, bivalent anti-hFcγRI-PspA-HSA, trivalent anti-hFcγRI-PspA, or trivalent anti-hFcγRI-PspA-HSA on day 0 and boosted on day 21. In each case, the amount of PspA administered will be equivalent (10 μg/mouse). Immunized mice will then be challenged i.n. two weeks post-boost with 1×10⁶ CFU Sp and monitored 21 days for survival. Infectious challenge of animals will be performed with strain A66.1 ⁷ , a mouse virulent capsule type 3 pneumococcus (family 1, clades 1,2), serologically similar to the family 1, clade 2, PspA of strain Rx1 ³⁷ utilized to construct the PspA-containing FPs. Culturing and counting the inoculums subsequent to challenge will be done to verify the exact CFU administered. Importantly, the above immunization regimen and challenge dose produces approximately 50% protection in hFcγRI Tg mice when immunizing with bivalent anti-hFcγRI-PspA ⁷ . The latter dosing/result will thus allow detection of differences in survival (positive and negative) between immunized groups. Should 100% protection be achieved with multiple FPs, the challenge dose will be increased to better distinguish between degrees of protective efficacy between FPs. To further delineate the protective efficacy of the FPs following immunization and challenge, bacterial burden will also be measured at various time intervals post-challenge in lung, liver, and spleen, as previously described by Dr. Gosselin ⁷ . The remaining tissue homogenate will be spun at 14,000×g for 20 min, and the clarified supernatant will be stored at −20° C. for future cytokine analysis.

Aim 2.2: Using the optimal FP formulation from Aim 2.1, determine the optimal FP dose that provides optimal protection in this challenge model.

Challenge experiments will be repeated utilizing the optimal FP formulation identified above and doses of PspA within FPs ranging from 3-30 μg/mouse. The challenge dose will be the highest dose used in Aim 2.1 for which protection was observed in Aim 2.1. Both survival and bacterial burden will then be measured. Once the optimal dose has been determined, immunizations will be carried out in WT, hFcRn Tg, hFcγRI Tg, versus hFcγRI/hFcRn-expressing mice to verify hFcRn and hFcγRI roles in the protection observed.

Aim 2.3: Examine the humoral and cellular immune responses to the FP vaccination.

Ab production: Sp-specific Ab production will be measured by ELISA as previously described by Dr. Gosselin ⁷ . Wells will be coated with live Sp or PspA. BSA-coated wells will be used as specificity controls for Sp and PspA. PspA and Sp-specific IgM, IgG isotypes, and IgA will be measured and responses compared between that of bronchioalveolar lavage (BAL) and serum from the same animals. We will also test for Abs cross-reactive with mouse and human tissues (potentially autoreactive Abs). In the case of human tissues, this will be done using paraffin embedded tissues from heart, lung, liver, kidney, and lymph node obtained commercially from anonymous donors. Tissues will be stained immunohistochemically as previously described by Dr. Gosselin ³⁸ using serum from FP-immunized mice. Isotype controls and Abs with known tissue specificity will be used as negative and positive controls, respectively. The ability of sera from FP-immunized mice to block FP binding to hFcγRI or FcRn will also be examined.

Cytokine production: ELISPOT will be used following immunization to identify T cell subsets producing specific cytokines using previously published methods ³⁹ . Cytokine production will also be measured after immunization, in vitro, as previously described by Dr. Gosselin ^(7,8) . Levels of selected cytokines produced in spleen cell supernatants in response to Ag (IL-2, IL-4, TNF-α, IFN-γ, and IL-5) will be measured using the multiplex Luminex assay. Cytokine mRNA generated following immunization will also be measured by RT-PCR at 1, 2, and 3 days post primary and booster immunization.

Histological analysis: It is possible that crosslinking hFcγRI could induce local toxicity or negative side effects, such as inflammation or local depletion of CD64+ cells. Therefore, histological and immunohistochemical analysis of infected tissues will be conducted to monitor and identify immune cell infiltrates and potential tissue damage/toxicity due to the immunogen/FP itself, as well as tissue damage due to infection. Mice will be euthanized at 12, 24, 48, 72, and 92 hours post-immunization or post-challenge. Post-immunization, lungs and nasal tract, including NALT, will be harvested. Post-challenge, lungs, spleen, lymph nodes (cervical, mediastinal, mesenteric, and submandibular), and nasal tract, including NALT, will be harvested. Tissues will be fixed in 2% paraformaldehyde in PBS. Tissues will then be processed for histology as previously described by one of the inventors

Potential outcomes and alternative approaches: Should there be any issues with the hFcRn component of the hFcγRI/hFcRn Tg mouse, we have the option of substituting the human FcRn-targeting sequence with the mouse equivalent, and using our hFcγRI Tg mouse model. In addition, hFcRn targeting of the anti-hFcγRI-PspA-HSA FP can be verified independently in the hFcRn Tg mice. In regard to the trivalent anti-hFcγRI-PspA, two separate studies using anti-hFcγRI mAb (22 mAb), from which our FP construct was derived, indicate trivalent interaction of this molecule with hFcγRI will produce a more effective immunogen ^(6,10) m. However, should the trivalent FP not produce protection superior to bivalent FP, we will focus on further testing/optimizing the bivalent anti-hFcγRI-HSA FP approach and subsequently combining it with an FcR-targeted DNA-prime FP-boost regimen (Aim 3). In regard to FcRn binding of the anti-hFcγRI-PspA-HSA FP, studies in WT mice and preliminary data herein (FIG. 5) indicate that HSA does bind to FcRn in FP form ⁴³ . However, the ability of FP Ag (PspA) to induce protective immunity may be compromised by conformational changes induced by the adjacent HSA component. In this case, the linker between PspA and HSA will be lengthened and/or alternative Ags, such as the highly cross-protective 100 amino acid proline-rich domain (PRD) of PspA ⁴⁴ will be tested. However, should protection studies using HSA-containing FPs not be superior to anti-hFcγRI-PspA FPs, we will focus on further development of the bivalent or trivalent anti-hFcγRI-PspA FP and subsequently combining it with an FcR-targeted DNA-prime FP-boost regimen, to further maximize vaccine potency (Aim 3). In regard to potential FP toxicity, it is expected that the optimized adjuvant-free FP vaccine regimen will induce comparable or superior mucosal Ab, T cell, and protective responses that are also less inflammatory than Prevnar®13, leading to improved protection and a more favorable safety profile. Should this not be the case, utilizing an anti-hFcγRI-PspA DNA vaccine we have recently generated (See Aim 3), we will attempt to overcome this caveat via a DNA-prime FP-boost regimen, based on the observation that DNA priming enhances the magnitude, quality, and longevity of protein vaccines ¹¹ . Alternatively, given the significant advantages of having an adjuvant-free mucosal vaccine platform ²³⁻²⁵ and the enhanced PspA/Sp-specific Ab production in response to FP, which we have observed using our prototype bivalent anti-hFcγRI-PspA ⁷ , it is possible to continue to develop, optimize, and test this approach in mice, in particular for those pathogens where protection is primarily Ab-mediated. In the latter case, it will be possible to rapidly move to a non-human primate (NHP) model, since the anti-hFcγRI component of the FP does bind to NHP FcγRI (See “Future Development Plans”). Additional potential caveats include: failure of DCs to mature in response to FPs, which could result in tolerance induction ⁴⁵⁻⁴⁸ , but could potentially be countered via increased hFcγRI crosslinking (Trivalent FP) or via a DNA-prime FP-boost regimen. It is also possible Abs will be generated to the FP itself, which then interfere with its function, or that cross-react with tissue Ags. In regard to anti-FP Abs, the inventors have already proven that the humanized anti-hFcγRI-PspA FP enhances immunity and protection in mice, despite the potential production of anti-FP Abs⁷. Importantly, this becomes less of an issue when studies move to NHPs and humans. Furthermore, EpiVax bioinformatics technology can be used to identify and remove epitopes responsible for the generation of FP blocking or autoreactive Abs (See attached Epivax letter)⁴⁹. It is also possible that despite the lack of an adjuvant, inflammation and tissue damage will occur post-FP immunization. This could be overcome by reduced FP dosage and increasing the number of boosts, or the use of a DNA-prime FP-boost in combination with lower FP doses. The latter may well facilitate FP dose reduction in any case, without compromising protection.

It is also possible that crosslinking hFcγRI could induce local toxicity or negative side effects, such as inflammation or local depletion of CD64+ cells. For example, studies demonstrating hFcγRI modulation as a consequence of extensive cross-linking mediated by whole mAb H22 (humanized anti-hFcγRI), and subsequent inhibition of opsinophagocytosis has been observed, which thereby impairs normal immune function ⁵⁰ . However, the observed inhibition in this case appeared to be dependent on the ability of whole 22 mAb to bind to hFcγRI via both Fab and Fc binding domains ⁵⁰ . In contrast, our anti-hFcγRI-Ag FPs lack the Fc domain, with the Fab regions also binding outside the IgG-Fc binding site (FIG. 6), the latter being a key advantage of utilizing our particular FP construct. Thus, it is unlikely our FPs will similarly impair opsinophagocytosis. Furthermore, it is difficult to induce internalization of all hFcγRI on a given cell, since there is continuous replacement of cell surface receptors, and effective blocking of opsinophagocytosis in vivo would require continuous administration of large amounts of FPs, something that is not required to induce an effective immune response when targeting Ag to hFcγRI ^(7,51) . Furthermore, assuming depletion of CD64+ cells does occur, it is likely to be transient, and data indicates the initial interaction with FP is sufficient to generate protective immunity ⁷ . Excessive inflammation will be dealt with by varying immunogen doses and vaccination regimens. Examples of the current and present technology is depicted in FIG. 6a . The current technology already has several specific characteristics/advantages in terms of an object of the present application. It contains a humanized targeting component (H22) that is bivalent and binds to hFcγRI outside the ligand-binding domain for IgG (FIG. 6a , top panels). The latter is a critical characteristic, since hFcγRI is a high affinity FcγR and is normally occupied by hIgG (FIG. 6a , top right panel). The bivalent nature of the targeting component also allows for cross-linking of hFcγRI in order to facilitate internalization and processing by APCs. The Ag PspA is linked to the targeting component. PspA is a protective surface protein Ag derived from Sp. It is conserved across the majority of Sp strains providing the potential for FP-mediated cross-strain protection. Importantly, we have already demonstrated that in this FP configuration, the PspA maintains its ability (structurally) to induce protective immune responses in mice. The current FP also contains a removable His tag for purification purposes.

Aim 3: Optimize FP platform immunogenicity and protective efficacy/longevity utilizing a DNA-prime FP-boost strategy.

DNA vaccines are a lower cost alternative to protein vaccines, can be more easily distributed, and stimulate humoral and cellular parenteral and mucosal immune responses^(52,53). DNA vaccine studies utilizing PspA as a protective immunogen have also been successfully conducted in a mouse model. ⁵⁴ Finally, a DNA-prime Protein-boost regimen has been shown to increase vaccine potency (humoral and cellular immune responses), as well as vaccine durability.¹⁶⁻²⁰. Thus, we will utilize the latter strategy to determine if we can further increase the potency and efficacy/longevity of our mucosal FP vaccine. A significant advantage of utilizing PspA as the immunogen is its potential to cross-protect against multiple Sp strains⁵⁵⁻⁵⁷. Therefore, additional challenge studies utilizing the optimized FP platform will also be conducted to determine the ability of FcR-targeted FP to cross-protect against Sp infection with several different Sp strains. While one object of the present application is establishing a highly potent adjuvant-free mucosal vaccine platform applicable to many pathogens, the latter studies will ultimately be important to also initially establishing this vaccine platform as a potentially viable approach for Sp vaccination.

Objectives: 1) Generate and test PspA and anti-hFcγRI-PspA FP-producing DNA vaccine vectors; 2) Identify the optimal human FcγRI-targeted DNA and DNA-prime FP-boost regimens; 3) Determine the breadth of protective immunity against multiple Sp challenge strains and compare the optimized FP vaccine to a licensed conjugate vaccine (Prevnar®13).

Aim 3.1: Generation and testing of PspA and anti-hFcγRI-PspA FP-producing DNA vaccine vectors.

PspA and anti-hFcγRI-PspA genes have been inserted into an optimized DNA vaccine expression cassette (FIG. 7) which has been optimized for clinical trials as described ^(58,59) . Thus, to facilitate comparison of DNA i.n. versus i d immunization routes, both i.n. and i.d. DNA immunization studies will initially be conducted using the bivalent anti-hFcγRI-PspA FP lacking the FcRn targeting component. Furthermore, if the trivalent FP proves more efficacious in Aim 2, the trivalent anti-hFcγRI-PspA gene lacking HSA will also be inserted and tested as a DNA vaccine. The function of the DNA vectors containing PspA and anti-hFcγRI-PspA have also been verified in vitro. Specifically, production of PspA bivalent anti-hFcγRI-PspA FP by mouse 3T3 cells following transient transfection with DNA vaccine vectors has been demonstrated by Western blot (FIG. 8).

Aim 3.2: Identify optimal DNA and DNA-prime FP-boost regimens.

Immunogenicity and challenge experiments: Intradermal and i.n. DNA-prime i.n. FP-boost regimens will be compared to the optimized i.n. FP regimen identified in Aim 2. Importantly, we will initially focus on DNA immunization via the i.n. route. Subsequently we will use i.d. DNA immunization to determine if the i.d. route might be superior to the use of i n immunization either independently and/or in the DNA-prime FP-boost approach. Intradermal DNA immunization will also be used should i.n. DNA immunization prove less stimulatory than that of the i.d. route. Experimental groups will include WT, hFcRn Tg, hFcγRI Tg, and hFcγRI/FcRn-expressing mice. Controls will also include mice receiving empty vector and vector plus PspA. Vaccinations will consist of 2 doses, 4 weeks apart. Blood will be collected before and 2 and 4 weeks post-immunization to measure Sp-specific Ab. Four weeks post-final boost, mice will be sacrificed to collect BAL, splenocytes, and lung lymphocytes to measure mucosal Ab and T cell responses. Mucosal and systemic Ab, T cell responses, and protection from Sp challenge will be examined as described in Aim 2. The optimal regimen that induces a significant improvement in protection, when compared to controls and the optimal FP regimen identified in Aim 2, will then be compared to Prevnar®13. DNA immunizations will be done as described below.

Intranasal DNA vaccination: We will use an established method for i.n. immunization with plasmid DNA Our successful use of this immunization strategy to enhance PspA (Sp)-specific Ab responses with our hFcγRI-targeted FP is demonstrated in FIG. 9. Briefly, DNA will be introduced into the nasal passages of mice in the form of Polyethyleneimine (PEI)-DNA complexes. PEI and DNA will be mixed in 5% glucose. The DNA will be used at a range of 0.5-5 mg/ml in the PEI-DNA mixture. The PEI will be mixed with the DNA to achieve N [Nitrogen residues in PEEP (Phosphate residues in DNA)] ratio of 6-8. The PEI-DNA mixture will then be kept at room temperature for 10 minutes to allow the complex to form, after which it will be used for immunization. Mice will be anesthetized and the PEI-DNA mixture will then be administered drop wise in alternating nostrils using a micropipette. We will initially use DNA doses ranging from 4 to 12 pmole per construct to optimize DNA dosing.

Gene gun DNA immunizations: This procedure has also been used successfully in our laboratory. Gene gun, or particle-mediated epidermal delivery (PMED) of vaccines, is a common method used for transcutaneous injection (TCI) of DNA vaccines into the epidermal layer of the skin. It differs from IM or ID DNA injection in that it results in direct intracellular delivery of the DNA into non-professional APCs (i.e. keratinocytes) and professional APC (i.e. Langerhans cells) in the epidermis ^(62,63) . A major benefit of immunizing the skin is the induction of both systemic and mucosal responses ⁶⁴⁻⁷² including highly disseminated mucosal IgA responses ^(73,74) . TCI in mice and NHPs has generated CD8 CTL ^(66,75,76) and mucosal IgA/Ab-secreting cells in the intestine ⁷⁷⁻⁸⁰ female reproductive tract ^(73,81) , upper ^(71,76) and lower respiratory tract⁸² and in the oral cavity ^(71,81,83) . In humans, TCI induced vaccine-specific IgA in saliva ⁸⁴ and the intestine ^(85,86) . The mechanism by which TCI induces mucosal responses is not entirely clear. Studies in mice suggest two possible mechanisms: 1) APCs migrate from the skin to mucosal inductive sites and activate local T cells ^(64,66,68,70,87) and/or 2) APCs migrate to regional draining lymph nodes and induce a mucosal homing phenotype on activated lymphocytes, which then home to mucosal effector sites ^(88,89) . PMED is one of the most efficient methods for DNA vaccine delivery and has induced protective levels of systemic Ab and CD8 T cell responses against a wide variety of diseases in mice, NHP and humans ^(78,90-92) . Importantly, like other TCI methods, PMED induces mucosal responses that contribute to improved protection from mucosal challenges ^(71,75,76) . PMED delivery of plasmid expressing the FcR-targeted vaccine may thus offer a potent strategy to induce/increase mucosal immunity. Therefore, DNA immunizations will be administered into the epidermal layer of the skin using the PowderJect XR-1 particle mediated epidermal delivery (PMED) research device as previously described ^(59,93) . Optimum DNA vaccine doses in mice consist of 2 μg DNA and 1 mg gold divided into two tandem sites per mouse. Two doses (prime+boost) will be administered per animal 4 weeks apart. Controls will include PBS or empty DNA vector.

Aim 3.3: Determine the breadth of protective immunity against multiple Sp challenge strains.

While one object of the present application is establishing a potentially highly potent adjuvant-free mucosal vaccine platform applicable to many pathogens, cross-protection studies will ultimately be important in initially establishing this vaccine platform as a potentially viable approach for Sp vaccination. Utilizing the optimal immunization regimen identified above, hFcγRI/FcRn-expressing mice will be immunized with the optimal vaccine regimen versus Prevnar®13 and will then be challenged with two additional strains of Sp [D39 (Serotype 2, PspA family 1, PspA clade 2) and 3JYP2670 (Serotype 3, PspA family 2, PspA clade 4)]. Protection will then be compared to that of strain A66.1 (Serotype 3, PspA family 1, PspA clades 1,2) ⁹⁴ . In regard to strain variability, while pairwise comparisons of PspA genes and proteins have been made, only the Rx1 strain from which the FP PspA was generated, was included ³⁷ . Thus, direct gene/protein comparisons of Rx1, A66.1, D39, and 3JYP2670 are not available. However, strains from family 1, clades 1,2 (analogous to A66.1) share 65-86% identity with the Rx1-derrived PspA. The case is similar for family 1, clade 2 strains (analogous to D39). Strains from family 2, clade 4 (analogous to 3JYP2670) share 54-57% identity with the Rx1 PspA. We will examine both protection and bacterial burden in the case of each challenge strain.

While we also recognize that the level of nasopharyngeal carriage is also an important correlate of vaccine efficacy against Sp infection, given one object of the present application is to development a novel and paradigm-changing vaccine platform, applicable to a range of infectious disease agents, we presently consider Sp carriage studies beyond the scope of this specific project.

Based on our preliminary studies using a DNA vaccine derived from the bivalent anti-hFcγRI-PspA FP administered i.n., in which we observed enhanced anti-Sp Ab production (FIG. 9), we expect we will be able to successfully develop and optimize an i.n. administered hFcR-targeted DNA vaccine-prime FP-boost regimen. Also, based on numerous studies demonstrating the ability of DNA-prime protein-boost strategies to increase vaccine potency, we expect that will similarly be the case for our hFcR-targeted DNA vaccine-prime FP-boost approach. However, should the DNA-prime FP-boost strategy fail to improve the efficacy of the FP vaccine, we will focus on the further development of hFcR-targeted DNA and FP vaccine strategies independently, since each approach may have beneficial characteristics, which could be valuable in future vaccine development, depending on the specific circumstances and pathogen involved.

It is contemplated that continued studies will focus on moving the innovative and paradigm altering (adjuvant-free) mucosal vaccine platform toward clinical trials. These studies will also take advantage of the ability of our FP(s) to bind to FcγRI in non-human primates (NHPs) (FIG. 10).

The present application is not limited to the use of recombinant protein/peptide epitopes, but, in the case of the FP vaccine, it is contemplated that it may be adapted to use with whole inactivated vaccines. This will be accomplished by substituting antigen with a moiety that binds inactivated organisms, such as inactivated F. tularensis, a biodefense pathogen, which the PI's laboratory has previously shown can enhance protection against F. tularensis challenge when targeted to FcR intranasally ^(8,9) .

Protection after FP immunization is eliminated in wildtype (WT-negative control) mice, which lack hFcγRI. Similar differences in immunity are also obtained when comparing PspA immunization of Tg mice with that of hFcγRI-targeted PspA FP, with the latter also producing enhanced anti-Sp Ab responses and protection. Data is provided in FIG. 11 demonstrating the successful production of trivalent and hFcγRI/FcRn-binding FPs, as well as the construction of PspA and anti-hFcγRI-PspA-containing DNA vaccine vectors (FIG. 7). Importantly, hFcRn-binding was only observed with the anti-hFcγRI-PspA-HSA FP and not anti-hFcγRI-PspA (negative control). Trivalent and HSA-containing FPs bind hFcγRI on hFcγRI-expressing U937 cells: Supernatants from FP construct-transfected NSO cells were screened by flow cytometry for the presence of FPs and the ability of trimeric and HSA-containing/FcRn-binding FPs to bind hFcγRI on U937 cells. Briefly, hFcγRI-expressing U937 cells were incubated for 2 hrs at 4° C. with culture medium, supernatant from non-transfected NSO cells, or supernatant from FP transfected cells in the presence of human IgG (to block non-specific FcR binding of Rb Abs), followed by 3 washes, a 1 h incubation with Rb anti-PspA or Rb anti-HSA Ab, 3 washes, and a 30 mm incubation with goat anti-Rb IgG-FITC. Cells were then washed, fixed, and analyzed by flow cytometry. **P<0.005, ***p<0.0001

FIG. 12 Map of pJG582 Vector—The pJG582 vector contains four tandem 5′ to 3′ DNA sequences encoding humanized VL-VH-VL-VH ScFv fragments derived from the humanized 22 (anti-human FcγRI) monoclonal antibody. These segments are joined by flexible linker sequences and flanked on the 5′ end by a CMV promoter, which induces FP production by eukaryotic cells. 3′ of the above V segments are XhoI/NotI restriction sites between which DNA sequences encoding antigen, such as PspA, or other molecules, can be inserted. 3′ of the XhoI/NotI insertion site is a neo resistance gene used for selection of transfected cells expressing the desired FP. In addition, within this vector is a signal sequence, which directs secretion of the FP by eukaryotic cells producing it.

FIG. 14 Map of pJV-7563 Vector (No secretion signal). Note: The sequences for PspA or the anti-human FcγRI-PspA fusion proteins have been inserted between NheI and Bgl-II restriction sites.

FIG. 15 Map of pUW-160s Vector (Contains secretion signal). This Plasmid has a Lysozyme secretion signal (Labeled as Lysozyme SP), which facilitates secretion of attached polypeptides through plasma membranes. Note: While making vaccine constructs the stuffer fragment has been replaced with either PspA or anti-human FcγRI-PspA fusion protein.

Generation of DNA Constructs: These constructs were generated from the original bivalent anti-FcγRI-PspA construct within the pjG582 plasmid.

Trivalent Anti-FcγRI-PspA (Construct B):

The cloning strategy of this construct was modified due to the repetitive sequence/domain nature of the construct itself. Instead of using an “inverse PCR” approach to insert two new restriction sites for the cloning of the third FcγRI, I had to use a “modular PCR” approach. Briefly, two PCR products were generated. The first used primers:

(SEQ ID NO: 1) FW 5′-ATAAGCGCTGGAGGCGGAGGTTCTAGTGA-3′ and (SEQ ID NO: 2) RV 5′-AGAATTCGCTAGC AGTCGAGCCTCCCCCACCGGT. This generated a PCR fragment that was 792 bp in length and encompassed nucleotides 1729 to 2520 in the parent construct. The second PCR used primers: FW 5′-AGAATTCATGGAAGAATCTCCCGTAGCCA-3′ (SEQ ID NO:3) and RV 5′-ATAAGCGCTGGTCGAGCCTCCCCCACCGGT-3′ (SEQ ID NO:4). This generated a PCR fragment that was 7.3kb in length and encompassed nucleotides 2521 to 1728 (wrapping). Each PCR product was digested with AfeI and EcoRI and ligated together to form the “new” parent construct, depicted below. Restriction sites on the top were introduced in the cloning reactions. Restriction sites on the bottom were present in the parent construct.

This construct was verified by sequencing.

Construct A is shown in FIG. 16.

The next step was to PCR the FcγRI portion using primers with flanking NheI and EcoRI sites (FW: 5′-TGCTAGCGGAGGCGGAGGTTCTAGTGA-3′ (SEQ ID NO:5) and RV: 5′-AGAATTCAGTCGAGCCTCCCCCACCGGT-3′ (SEQ ID NO:6)). This PCR product and the new parent construct (above) were digested with NheI and EcoRI and ligated together to form the construct below.

This construct was verified by sequencing with the caveat that the middle FcγRI section could not be fully sequenced (see below). However, this region was sequenced in Construct A (shown in FIG. 16).

Trivalent Anti-FcγRI-PspA (Construct B):

Construct A was then subject to inverse PCR for introduction of two new restriction sites downstream of PspA for cloning in the HuSA. One PCR was performed using the primers: FW 5′-ATCGTACGCACCACCACCACCACCACTGA-3′ (SEQ ID NO:7) and RV 5′-ATCGTACGTGTACAACCGCCTGATCCACCCTCGAGTTCTGGGGCTGGAGTTTC T-3′ (SEQ ID NO:8). This PCR product was digested with BsiWI and ligated together to form the following construct.

Bivalent Anti-FcγRI-PspA-HuSA (Construct D):

Construct C is shown in FIG. 17.

The HuSA sequence was amplified using the following primers: FW 5′-tgtacactagagaagtgctgtgccgct-3′ (SEQ ID NO:9) and RV 5′-cgtacgtaagcctaaggcagcttgactt-3′ (SEQ ID NO:10). This PCR product and Construct C was digested with BsiWI and BsrGI and ligated together to form the following construct. This construct was verified by sequencing.

Bivalent Anti-FcγRI-PspA-HuSA (Construct D):

Construct D is shown in FIG. 17.

Construct B was subject to the same inverse PCR as Construct A to form the following construct:

Trivalent Anti-FcγRI-PspA-HuSA (Construct F):

Construct E is shown in FIG. 18.

The HuSA PCR product and Construct E was digested with BsiWI and BsrGI and ligated together to form the following construct. This construct was verified by sequencing with the caveat that the middle FcγRI section could not be fully sequenced (see below). However, this region was sequenced in Construct D.

Trivalent Anti-FcγRI-PspA-HuSA (Construct F):

Construct F is shown in FIG. 18.

To form the non-targeting PspA-HuSA construct, Construct D was digested with AgeI, the large, vector band was gel extracted and ligated to form the following construct. This construct was verified by sequencing.

Non-FcγRI-Targeted PspA-HuSA (Construct G):

Construct G is shown in FIG. 19.

Each construct has been verified by sequencing to the extent that the technology allows. The middle FcγRI domain for Construct B and Construct F could not be verified because unique sequencing primers could not be designed to cover this region due to the repetitive nature of the construct. However, because this region was sequence verified in Construct A and D, it is believed that it is mutation free in the trivalent forms.

For unknown reasons, the AfeI site that was introduced through modular PCR caused problems with sequencing reactions and subsequent PCR. Regardless, the constructs do cut with AfeI with the correct predicted sizes, therefore, it is believed that this site is structurally sound even though it has not been proven with sequence data.

A comparison of the proposed Sp and flu FP vaccines to licensed vaccines is presented in Table I. It is contemplated that the Ag component within the FP may be replaced with a molecule, which binds inactivated microorganisms such as inactivated F. tularensis (iFt), with which one of the present inventors has demonstrated the ability to protect against the highly lethal human virulent strain Ft SchuS4 via FcR targeting (i.n administered iFt). Importantly, this would add yet another major capability to this platform, significantly expanding its application to inactivated microbial vaccines.

TABLE I Comparison of Proposed Sp and flu FP Vaccines to Licensed Vaccines Sp or HA FP FluMist (FcR Prevnar FluZone (live Key Features targeted) (Conjugate) (killed) attenuated) Induces protective Ab YES YES YES YES Induces protective T cell responses YES NO NO YES Induces mucosal immunity YES NO NO YES Single Ag affords cross-protection YES YES NO SLIGHT against different strains Requires adjuvant NO YES YES NO Induces long-term immunity YES NO NO NO without annual boosting Rapid manufacture YES NO NO NO Stability supports long-term YES YES NO NO stockpiling Very safe in all segments of the YES YES YES NO population

One object of the present application is to identify a single FcR-targeted vaccine platform that affords optimal protection to bacterial and viral mucosal challenge utilizing mouse bacterial and viral infection models, which is also broadly applicable to the majority of respiratory biodefense (Table 2), as well as non-biodefense pathogens. However, it is recognized that the FP, DNA, or DNA prime-FP boost platforms could each provide unique advantages suitable to specific pathogens. Thus, these studies could also lead to the advancement of pathogen-specific vaccine design(s) for individual and combination vaccines, dependent on the pathogen (s) of interest (bacterial or viral), route of entry (mucosal or parenteral), and protective response(s) (humoral or cellular) required. Once the optimal vaccine regimen/platform is identified, similar studies will then be conducted in NHPs. Interim's will be: 1) To determine if increasing the valency of the hFcγRI targeting component in the FP is superior to the proven bivalent FP; 2) To determine if adding an FcRn targeting component to the FP will further increase the potency of the bivalent or trivalent FP; 3) To determine if a hFcγRI-targeted DNA vaccine is efficacious vs. non-targeted DNA vaccine; 4) To determine if a hFcγRI-targeted DNA prime-FP boost regimen is superior to DNA or FP regimens; 5) To determine if a multipathogen (combination) vaccine platform is efficacious by combining optimized Sp and flu vaccine platforms. Once NHP studies are completed demonstrating the efficacy of this approach in this model, the final platform formulation will be put into large-scale production. However, prior to initiating large scale production and clinical studies, the PspA and HA Ags used will be re-evaluated to determine if in the interim, superior Ags more appropriate for clinical application against these pathogens have been identified. Also, protective Ags against biodefense pathogens such as Ft may have been identified at this point, which could be used with this platform, expanding the potential for clinical trials with Category A-C biodefense pathogens, in addition to those pathogens utilized in these studies.

TABLE 2 Biothreat Agents That Present Risk for Aerosol/Mucosal Delivery Category A Category B Category C Anthrax Coxiella burnetti (Q fever) Influenza Pneumonic plague Brucella species SARS and associated (brucellosis) coronaviruses Tularemia Burkholderia mallei (glanders) Filoviruses Equine encephalitis viruses Arenaviruses Bunyaviruses

The contents of each of the below-identified references are hereby incorporated by reference.

1. Nguyen, H. H., Moldoveanu, Z., Novak, M. J., van Ginkel, F. W., Ban, E., Kiyono, H., McGhee, J. R. & Mestecky, J. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 254, 50-60 (1999).

2. Renegar, K. B., Small, P. A., Jr., Boykins, L. G. & Wright, P. F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173, 1978-1986 (2004).

3. Ito, R., Ozaki, Y. A., Yoshikawa, T., Hasegawa, H., Sato, Y., Suzuki, Y., Inoue, R., Morishima, T., Kondo, N., Sata, T., Kurata, T. & Tamura, S. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 21, 2362-2371 (2003).

4. Chen, Z., Kadowaki, S., Hagiwara, Y., Yoshikawa, T., Matsuo, K., Kurata, T. & Tamura, S. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18, 3214-3222 (2000).

5. McGhee, J. R. A mucosal gateway for vaccines. Nat Biotechnol 29, 136-138 (2011).

6. Guyre, C. A., Keler, T., Swink, S. L., Vitale, L. A., Graziano, R. F. & Fanger, M. W. Receptor modulation by Fc gamma RI-specific fusion proteins is dependent on receptor number and modified by IgG. J Immunol 167, 6303-6311 (2001).

7. Bitsaktsis, C., Iglesias, B. V., Li, Y., Colino, J., Snapper, C. M., Hollingshead, S. K., Pham, G., Gosselin, D. R. & Gosselin, E. J. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcgamma receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity. Infect Immun 80, 1166-1180 (2012).

8. Rawool, D. B., Bitsaktsis, C., Li, Y., Gosselin, D. R., Lin, Y., Kurkure, N. V., Metzger, D. W. & Gosselin, E. J. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 180, 5548-5557 (2008).

9. Iglesias, B. V., Bitsaktsis, C., Pham, G., Drake, J. R., Hazlett, K. R., Porter, K. & Gosselin, E. J. Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen. Immunology and cell biology 91, 139-148 (2013).

10. Keler, T., Guyre, P. M., Vitale, L. A., Sundarapandiyan, K., van De Winkel, J. G., Deo, Y. M. & Graziano, R. F. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol 165, 6738-6742 (2000).

11. Lu, S. Heterologous prime-boost vaccination. Curr Opin Immunol 21, 346-351 (2009).

12. Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M. & Anderson, C. L. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 45, 4983-4990 (2006).

13. Kenanova, V. E., Olafsen, T., Salazar, F. B., Williams, L. E., Knowles, S. & Wu, A. M. Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Eng Des Sel 23, 789-798 (2010).

14. van Montfoort, N., t Hoen, P. A., Mangsbo, S. M., Camps, M. G., Boross, P., Melief, C. J., Ossendorp, F. & Verbeek, J. S. Fcgamma receptor IIb strongly regulates Fcgamma receptor-facilitated T cell activation by dendritic cells. J Immunol 189, 92-101 (2012).

15. Boruchov, A. M., Heller, G., Veri, M. C., Bonvini, E., Ravetch, J. V. & Young, J. W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 115, 2914-2923 (2005).

16. Wei, C. J., Boyington, J. C., McTamney, P. M., Kong, W. P., Pearce, M. B., Xu, L., Andersen, H., Rao, S., Tumpey, T. M., Yang, Z. Y. & Nabel, G. J. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064 (2010).

17. Haddad, D., Liljeqvist, S., Stahl, S., Hansson, M., Perlmann, P., Ahlborg, N. & Berzins, K. Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol. Scandinavian journal of immunology 49, 506-514 (1999).

18. Leung, L., Srivastava, I. K., Kan, E., Legg, H., Sun, Y., Greer, C., Montefiori, D. C., zur Megede, J. & Barnett, S. W. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 18, 991-1001 (2004).

19. Otten, G. R., Schaefer, M., Doe, B., Liu, H., Srivastava, I., Megede, J., Kazzaz, J., Lian, Y., Singh, M., Ugozzoli, M., Montefiori, D., Lewis, M., Driver, D. A., Dubensky, T., Polo, J. M., Donnelly, J., O'Hagan, D. T., Barnett, S. & Ulmer, J. B. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 79, 8189-8200 (2005).

20. Tanghe, A., D'Souza, S., Rosseels, V., Denis, O., Ottenhoff, T. H., Dalemans, W., Wheeler, C. & Huygen, K. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 69, 3041-3047 (2001).

21. Kensil, C. R., Mo, A. X. & Truneh, A. Current vaccine adjuvants: an overview of a diverse class. Front Biosci 9, 2972-2988 (2004).

22. McGhee, J. R. & Kiyono, H. Effective mucosal immunity. Current concepts for vaccine delivery and immune response analysis. Int J Technol Assess Health Care 10, 93-106 (1994).

23. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat Med 11, S45-53 (2005).

24. Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nature reviews. Immunology 6, 148-158 (2006).

25. Mestecky, J. & McGhee, J. R. Prospects for human mucosal vaccines. Advances in experimental medicine and biology 327, 13-23 (1992).

26. Areas, A. P., Oliveira, M. L., Miyaji, E. N., Leite, L. C., Aires, K. A., Dias, W. O. & Ho, P. L. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun 321, 192-196 (2004).

27. Boyaka, P. N., Lillard, J. W., Jr. & McGhee, J. Interleukin 12 and innate molecules for enhanced mucosal immunity. Immunol Res 20, 207-217 (1999).

28. McCluskie, M. J. & Weeratna, R. D. Novel adjuvant systems. Curr Drug Targets Infect Disord 1, 263-271 (2001).

29. Gosselin, E. J., Bitsaktsis, C., Li, Y. & Iglesias, B. V. Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens. Arch Immunol Ther Exp (Warsz) 57, 311-323 (2009).

30. Lu, L., Palaniyandi, S., Zeng, R., Bai, Y., Liu, X., Wang, Y., Pauza, C. D., Roopenian, D. C. & Zhu, X. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol 85, 10542-10553 (2011).

31. Ye, L., Zeng, R., Bai, Y., Roopenian, D. C. & Zhu, X. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 29, 158-163 (2011).

32. Dickinson, B.L., Badizadegan, K., Wu, Z., Ahouse, J. C., Zhu, X., Simister, N. E., Blumberg, R. S. & Lencer, W. I. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104, 903-911 (1999).

33. Kobayashi, N., Suzuki, Y., Tsuge, T., Okumura, K., Ra, C. & Tomino, Y. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 282, F358-365 (2002).

34. Hershberg, R. M., Cho, D. H., Youakim, A., Bradley, M. B., Lee, J. S., Framson, P. E. & Nepom, G. T. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells. J Clin Invest 102, 792-803 (1998).

35. Sardella, A., Voisin, C., Nickmilder, M., Dumont, X., Annesi-Maesano, I. & Bernard, A. Nasal epithelium integrity, environmental stressors, and allergic sensitization: a biomarker study in adolescents. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals 17, 309-318 (2012).

36. Schaper, C., Gustavus, B., Koch, B., Ewert, R., Felix, S.B., Kunkel, G., Noga, O. & Glaser, S. Effect of fluticasone on neuropeptides in nasal lavage in persistent allergic rhinitis. Journal of investigational allergology & clinical immunology 20, 214-221 (2010).

37. Hollingshead, S. K., Becker, R. & Briles, D. E. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68, 5889-5900 (2000).

38. Gosselin, E. J., Dennett, J. C., Sorenson, G. D., Pettengill, O. S. & Cate, C. C. Immunocytochemical staining of cytocentrifuge prepared cultured cells: nonspecific staining and its elimination. Histochem J 17, 847-858 (1985).

39. Bumann, D., Metzger, W. G., Mansouri, E., Palme, O., Wendland, M., Hurwitz, R., Haas, G., Aebischer, T., von Specht, B. U. & Meyer, T. F. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 20, 845-852 (2001).

40. Bitsaktsis, C., Rawool, D. B., Li, Y., Kurkure, N. V., Iglesias, B. & Gosselin, E. J. Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. J Immunol 182, 4899-4909 (2009).

41. Gosselin, E. J., Cate, C. C., Pettengill, O. S. & Sorenson, G. D. Immunocytochemistry: its evolution and criteria for its application in the study of epon-embedded cells and tissue. Am J Anat 175, 135-160 (1986).

42. Gosselin, E. J. & Parker, D. C. Class II MHC molecules and antigen enter the same vesicles during internalization by resting B lymphocytes. Cell Immunol 129, 404-413 (1990).

43. Andersen, J. T., Daba, M. B., Berntzen, G., Michaelsen, T. E. & Sandlie, I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 285, 4826-4836 (2010).

44. Daniels, C. C., Coan, P., King, J., Hale, J., Benton, K. A., Briles, D. E. & Hollingshead, S. K. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun 78, 2163-2172 (2010).

45. Bagley, K. C., Abdelwahab, S. F., Tuskan, R. G. & Lewis, G. K. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect Immun 71, 6850-6856 (2003).

46. Mowat, A. M. Dendritic cells and immune responses to orally administered antigens. Vaccine 23, 1797-1799 (2005).

47. Saint-Lu, N., Tourdot, S., Razafindratsita, A., Mascarell, L., Berjont, N., Chabre, H., Louise, A., Van Overtvelt, L. & Moingeon, P. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 64, 1003-1013 (2009).

48. Sun, J. B., Czerkinsky, C. & Holmgren, J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scandinavian journal of immunology 71, 1-11 (2010).

49. Moise, L., Song, C., Martin, W. D., Tassone, R., De Groot, A. S. & Scott, D. W. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin Immunol 142, 320-331 (2012).

50. Wallace, P. K., Keler, T., Guyre, P. M. & Fanger, M. W. Fc gamma RI blockade and modulation for immunotherapy. Cancer Immunol Immunother 45, 137-141 (1997).

51. Adamova, E., Walsh, M. C., Gosselin, D. R., Hale, K., Preissler, M. T., Graziano, R. F. & Gosselin, E. J. Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system. Immunological investigations 34, 417-429 (2005).

52. Yager, E. J., Dean, H. J. & Fuller, D. H. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev Vaccines 8, 1205-1220 (2009).

53. Fuller, D. H., Loudon, P. & Schmaljohn, C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40, 86-97 (2006).

54. Miyaji, E. N., Ferreira, D. M., Lopes, A. P., Brandileone, M. C., Dias, W. O. & Leite, L. C. Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun 70, 5086-5090 (2002).

55. Nguyen, C. T., Kim, S. Y., Kim, M. S., Lee, S. E. & Rhee, J. H. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 29, 5731-5739 (2011).

56. Goulart, C., Darrieux, M., Rodriguez, D., Pimenta, F. C., Brandileone, M. C., de Andrade, A. L. & Leite, L. C. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine 29, 1634-1642 (2011).

57. Briles, D. E., Hollingshead, S. K., King, J., Swift, A., Braun, P. A., Park, M. K., Ferguson, L. M., Nahm, M. H. & Nabors, G. S. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182, 1694-1701 (2000).

58. Drape, R. J., Macklin, M. D., Barr, L. J., Jones, S., Haynes, J. R. & Dean, H. J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24, 4475-4481 (2006).

59. Roy, M. J., Wu, M. S., Barr, L. J., Fuller, J. T., Tussey, L. G., Speller, S., Culp, J., Burkholder, J. K., Swain, W. F., Dixon, R. M., Widera, G., Vessey, R., King, A., Ogg, G., Gallimore, A., Haynes, J. R. & Heydenburg Fuller, D. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764-778 (2000).

60. Shim, B. S., Park, S. M., Quan, J. S., Jere, D., Chu, H., Song, M. K., Kim, D. W., Jang, Y. S., Yang, M. S., Han, S. H., Park, Y. H., Cho, C. S. & Yun, C. H. Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. BMC immunology 11, 65 (2010).

61. Torrieri-Dramard, L., Lambrecht, B., Ferreira, H. L., Van den Berg, T., Klatzmann, D. & Bellier, B. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Molecular therapy: the journal of the American Society of Gene Therapy 19, 602-611 (2011).

62. Lawson, L. B., Clements, J. D. & Freytag, L. C. Mucosal immune responses induced by transcutaneous vaccines. Curr Top Microbiol Immunol 354, 19-37 (2012).

63. Condon, C., Watkins, S. C., Celluzzi, C. M., Thompson, K. & Falo, L. D., Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2, 1122-1128 (1996).

64. Chang, S. Y., Cha, H. R., Igarashi, O., Rennert, P.D., Kissenpfennig, A., Malissen, B., Nanno, M., Kiyono, H. & Kweon, M. N. Cutting edge: Langerin+ dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. Journal of immunology 180, 4361-4365 (2008).

65. Lawson, L. B., Clements, J. D. & Freytag, L. C. Mucosal immune responses induced by transcutaneous vaccines. Curr Top Microbiol Immunol 354, 19-37 (2012).

66. Belyakov, I. M., Hammond, S. A., Ahlers, J. D., Glenn, G. M. & Berzofsky, J. A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113, 998-1007 (2004).

67. Daynes, R. A., Enioutina, E. Y., Butler, S., Mu, H. H., McGee, Z. A. & Araneo, B. A. Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Infect Immun 64, 1100-1109 (1996).

68. Enioutina, E. Y., Visic, D. & Daynes, R. A. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18, 2753-2767 (2000).

69. Glenn, G. M., Scharton-Kersten, T., Vassell, R., Mallett, C. P., Hale, T. L. & Alving, C. R. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161, 3211-3214 (1998).

70. Enioutina, E. Y., Bareyan, D. & Daynes, R. A. TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines. Vaccine 26, 601-613 (2008).

71. Chen, D., Periwal, S. B., Larrivee, K., Zuleger, C., Erickson, C. A., Endres, R. L. & Payne, L. G. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol 75, 7956-7965 (2001).

72. Czerkinsky, C. & Holmgren, J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol 354, 1-18 (2012).

73. Liard, C., Munier, S., Arias, M., Joulin-Giet, A., Bonduelle, O., Duffy, D., Shattock, R. J., Verrier, B. & Combadiere, B. Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 29, 6379-6391 (2011).

74. Mishra, D., Mishra, P.K., Dubey, V., Nahar, M., Dabadghao, S. & Jain, N. K. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur J Pharm Sci 33, 424-433 (2008).

75. Fuller, D. H., Raj akumar, P. A., Wilson, L. A., Trichel, A. M., Fuller, J. T., Shipley, T., Wu, M. S., Weis, K., Rinaldo, C. R., Haynes, J. R. & Murphey-Corb, M. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 76, 3309-3317 (2002).

76. Loudon, P. T., Yager, E. J., Lynch, D. T., Narendran, A., Stagnar, C., Franchini, A. M., Fuller, J. T., White, P. A., Nyuandi, J., Wiley, C. A., Murphey-Corb, M. & Fuller, D. H. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 5, e11021 (2010).

77. Ghose, C., Kalsy, A., Sheikh, A., Rollenhagen, J., John, M., Young, J., Rollins, S. M., Qadri, F., Calderwood, S. B., Kelly, C. P. & Ryan, E. T. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infection and immunity 75, 2826-2832 (2007).

78. Haynes, J. R., Fuller, D. H., McCabe, D., Swain, W. F. & Widera, G. Induction and characterization of humoral and celllar immune responses elicited via gene gun-mediated nucleic acid immunization. Adv. Drug Delivery Rev. 21, 3-18. (1996).

79. John, M., Bridges, E. A., Miller, A. O., Calderwood, S. B. & Ryan, E. T. Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. Vaccine 20, 2720-2726 (2002).

80. Yu, J., Cassels, F., Scharton-Kersten, T., Hammond, S. A., Hartman, A., Angov, E., Corthesy, B., Alving, C. & Glenn, G. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infection and immunity 70, 1056-1068 (2002).

81. Gockel, C. M., Bao, S. & Beagley, K. W. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol Immunol 37, 537-544 (2000).

82. Uddowla, S., Freytag, L. C. & Clements, J. D. Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine 25, 7984-7993 (2007).

83. Berry, L. J., Hickey, D. K., Skelding, K. A., Bao, S., Rendina, A. M., Hansbro, P. M., Gockel, C. M. & Beagley, K. W. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72, 1019-1028 (2004).

84. Etchart, N., Hennino, A., Friede, M., Dahel, K., Dupouy, M., Goujon-Henry, C., Nicolas, J. F. & Kaiserlian, D. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 25, 6891-6899 (2007).

85. Glenn, G. M., Flyer, D. C., Ellingsworth, L. R., Frech, S. A., Frerichs, D. M., Seid, R. C. & Yu, J. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 6, 809-819 (2007).

86. McKenzie, R., Bourgeois, A. L., Frech, S. A., Flyer, D. C., Bloom, A., Kazempour, K. & Glenn, G. M. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25, 3684-3691 (2007).

87. Enioutina, E. Y., Bareyan, D. & Daynes, R. A. Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo expand the scope of their antigen presenting properties. Vaccine 25, 1236-1249 (2007).

88. Iwata, M., Hirakiyama, A., Eshima, Y., Kagechika, H., Kato, C. & Song, S. Y. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527-538 (2004).

89. Saurer, L., McCullough, K. C. & Summerfield, A. In vitro induction of mucosa-type dendritic cells by all-trans retinoic acid. J Immunol 179, 3504-3514 (2007).

90. Dean, H. J., Fuller, D. & Osorio, J. E. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp Immunol Microbiol Infect Dis 26, 373-388 (2003).

91. Haynes, J. R. Particle-mediated DNA vaccine delivery to the skin. Expert Opin Biol Ther 4, 889-900 (2004).

92. Payne, L. G., Fuller, D. H. & Haynes, J. R. Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. Curr Opin Mol Ther 4, 459-466 (2002).

93. Pertmer, T. M., Eisenbraun, M. D., McCabe, D., Prayaga, S. K., Fuller, D. H. & Haynes, J. R. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13, 1427-1430 (1995).

94. Darrieux, M., Miyaji, E. N., Ferreira, D. M., Lopes, L. M., Lopes, A. P., Ren, B., Briles, D. E., Hollingshead, S. K. & Leite, L. C. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun 75, 5930-5938 (2007). 

What is claimed is:
 1. An immunogenic fusion protein for use as a mucosal vaccine comprising: i) one or more FcγR1-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more FcRn-binding domains.
 2. The immunogenic fusion protein of claim 1, wherein the one or more FcγR1 binding domains is an anti-FcγR1 antibody or a fragment thereof.
 3. The immunogenic fusion protein of any of claims 1-2, wherein the one or more FcRn binding domains is selected from the group consisting of an anti-FcRn antibody or a fragment thereof and a mammalian serum albumin protein or a fragment thereof.
 4. The immunogenic fusion protein of any of claims 1-3, wherein the anti-FcγR1 antibody fragment comprises SEQ ID NO:24.
 5. The immunogenic fusion protein of any of claims 1-4, wherein the fusion protein comprises at least two FcγR1 binding domains.
 6. The immunogenic fusion protein of any of claims 1-4, wherein the fusion protein comprises at least three FcγR1 binding domains.
 7. The immunogenic fusion protein of any of claims 1-6, wherein the FcRn binding domain is a fragment of human serum albumin comprising domain III.
 8. The immunogenic fusion protein of any of claims 1-6, wherein the FcRn binding domain is a variant of domain III of human serum albumin having at least 90% amino acid identity.
 9. The immunogenic fusion protein of claim 7, wherein the fragment of human serum albumin comprising domain III comprises SEQ ID NO:
 25. 10. The immunogenic fusion protein of any of claims 1-9, wherein the infectious disease organism is a bacterial or viral pathogen.
 11. The immunogenic fusion protein of any of claims 1-10, wherein the FcγR1 is human.
 12. The immunogenic fusion protein of any of claims 1-11, wherein the FcRn is human.
 13. The immunogenic fusion protein of claim 10, wherein the pathogen is selected from the group consisting of Streptococcus pneumonia, Neisseria meningitidis, Haemophilus influenza, Klebsiella spp., Pseudomonas spp., Salmonella spp., Shigella spp., and Group B streptococci, Bacillus anthracis adenoviruses; Bordetella pertussus; Botulism; bovine rhinotracheitis; Brucella spp.; Branhamella catarrhalis; canine hepatitis; canine distemper; Chlamydiae; Cholera; coccidiomycosis; cowpox; tularemia; filoviruses; arenaviruses; bunyaviruses; cytomegalovirus; cytomegalovirus; Dengue fever; dengue toxoplasmosis; Diptheria; encephalitis; Enterotoxigenic Escherichia coli; Epstein Barr virus; equine encephalitis; equine infectious anemia; equine influenza; equine pneumonia; equine rhinovirus; feline leukemia; flavivirus; Burkholderia mallei; Globulin; Haemophilus influenza type b; Haemophilus influenzae; Haemophilus pertussis; Helicobacter pylori; Hemophilus spp.; hepatitis; hepatitis A; hepatitis B; Hepatitis C; herpes viruses; HIV; HIV-1 viruses; HIV-2 viruses; HTLV; Influenza; Japanese encephalitis; Klebsiellae spp. Legionella pneumophila; leishmania; leprosy; lyme disease; malaria immunogen; measles; meningitis; meningococcal; Meningococcal Polysaccharide Group A, Meningococcal Polysaccharide Group C; mumps; Mumps Virus; mycobacteria; Mycobacterium tuberculosis; Neisseria spp; Neisseria gonorrhoeae; ovine blue tongue; ovine encephalitis; papilloma; SARS and associated coronaviruses; parainfluenza; paramyxovirus; paramyxoviruses; Pertussis; Plague; Coxiella bumetti; Pneumococcus spp.; Pneumocystis carinii; Pneumonia; Poliovirus; Proteus species; Pseudomonas aeruginosa; rabies; respiratory syncytial virus; rotavirus; Rubella; Salmonellae; schistosomiasis; Shigellae; simian immunodeficiency virus; Smallpox; Staphylococcus aureus; Staphylococcus spp.; Streptococcus pyogenes; Streptococcus spp.; swine influenza; tetanus; Treponema pallidum; Typhoid; Vaccinia; varicella-zoster virus; and Vibrio cholera and combinations thereof.
 14. The immunogenic fusion protein of any of claims 1-13, wherein the fusion protein enhances transepithelial transport of the fusion protein to the nasal-associated lymphoid tissue (NALT) and enhances FcγR1 crosslinking by the fusion protein on antigen presenting cells (APC) within the NALT.
 15. The immunogenic fusion protein of any of claims 1-14, wherein the antigen is selected from the group consisting of: PspA (Streptococcus pneumonia), gp120 (HIV), hemagglutinin (influenza) and neuraminidase (influenza)
 16. The immunogenic fusion protein of claim 1, wherein the fusion protein comprises SEQ ID NO:12.
 17. The immunogenic fusion protein of claim 1, wherein the fusion protein comprises SEQ ID NO:13.
 18. The immunogenic fusion protein of any of claims 1-17, further comprising a cleavable protein sequence and/or affinity tag to aid in purification.
 19. The immunogenic fusion protein of any of claims 18, wherein the affinity tag comprises at least 6 histidine residues.
 20. The immunogenic fusion protein of any of claims 1-19, further comprising a secretion signal to facilitate secretion of the protein through plasma membrane.
 21. The immunogenic fusion protein of claim 20, wherein the secretion signal is a lysozyme secretion signal.
 22. The immunogenic fusion protein of any of claims 1-21, wherein upon administration to a subject, the fusion protein generates protection against both mucosal and non-mucosal pathogens.
 23. The immunogenic fusion protein of any of claims 1-21, wherein upon administration to a subject, the fusion protein generates protection at mucosal and non-mucosal sites.
 24. A nucleic acid sequence encoding the immunogenic fusion protein of any of claims 1-23.
 25. The nucleic acid sequence of claim 24, wherein the nucleic acid comprises the sequence of SEQ ID NO:20.
 26. The nucleic acid sequence of claim 24, wherein the nucleic acid comprises the sequence of SEQ ID NO:23.
 27. A vector comprising the nucleic acid sequence of any of claims 24-26.
 28. The vector of claim 27, wherein the vector can be used as a nucleic acid vaccine.
 29. The vector of claim 28, wherein the vector comprises the sequence of SEQ ID NO:17.
 30. The vector of claim 28, wherein the vector comprises the sequence of SEQ ID NO:18.
 31. A pharmaceutical composition comprising a fusion protein of any of claims 1-23 and a pharmaceutically acceptable carrier.
 32. The pharmaceutical composition of claim 31, wherein the composition comprises a plurality of different fusion proteins, wherein each fusion protein comprises a different infectious disease antigen.
 33. The pharmaceutical composition of claim 32, wherein the different infectious disease antigens are from the same organism.
 34. The pharmaceutical composition of claim 32, wherein the different infectious disease antigens are from different organisms.
 35. The pharmaceutical composition of any of claims 31-34, wherein the composition lacks an adjuvant.
 36. A pharmaceutical composition comprising the nucleic acid molecule of any of claims 24-30 and a pharmaceutically acceptable carrier.
 37. The pharmaceutical composition of claim 36, formulated as a nucleic acid vaccine.
 38. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of an immunogenic fusion protein of any of claims 1-23.
 39. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of nucleic acid of any of claims 24-30.
 40. The method of claim 38 or 39, wherein the subject is administered a single dose.
 41. The method of claim 38 or 39, wherein the subject is administered one or more sequential doses.
 42. The method of claim 41, wherein the fusion protein or nucleic acid is administered as a component of a homologous or heterologous prime/boost vaccine regimen.
 43. The method of claim 42, wherein the fusion protein is administered as a prime and is subsequently boosted by administration of the nucleic acid to the subject.
 44. The method of claim 42, wherein the nucleic acid is administered as a prime and is subsequently boosted by administration of the fusion protein to the subject.
 45. The method of claim 42, wherein the fusion protein is administered as a prime and is subsequently boosted by administration of the fusion protein to the subject.
 46. The method of claim 42, wherein the nucleic acid is administered as a prime and is subsequently boosted by administration of the nucleic acid to the subject.
 47. The method of any of claims 39-46, wherein the subject is human.
 48. The method of claim 39, wherein the nucleic acid is administered intradermally or intranasally.
 49. The method of claim 48, wherein intranasal administration induces secretion of the immunogenic fusion protein into the nasal tract.
 50. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of nucleic acid encoding any one of the following, or a combination thereof; iv) an immunogenic fusion protein comprising: c. one or more antigens from one or more infectious disease organisms; and d. one or more FcRn-binding domains; v) an immunogenic fusion protein comprising: a) one or more FcγR1-binding domains; and b) one or more antigens from one or more infectious disease organisms; and vi) an immunogenic fusion protein comprising: a) one or more FcγR1-binding domains; b) one or more antigens from one or more infectious disease organisms; and c) one or more FcRn-binding domains.
 51. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of a fusion protein of any one of the following, or a combination thereof; iv) an immunogenic fusion protein comprising: c) one or more antigens from one or more infectious disease organisms; and d) one or more FcRn-binding domains; v) an immunogenic fusion protein comprising: a) one or more FcγR1-binding domains; and b) one or more antigens from one or more infectious disease organisms; and vi) an immunogenic fusion protein comprising: a) one or more FcγR1-binding domains; b) one or more antigens from one or more infectious disease organisms; and c) one or more FcRn-binding domains.
 52. An immunogenic fusion protein for use as a cancer vaccine comprising: iii) one or more FcγR1-binding domains; iv) one or more antigens from one or more cancers; and iii) one or more FcRn-binding domains.
 53. The immunogenic fusion protein of claim 52, wherein the one or more FcγR1 binding domains is an anti-FcγR1 antibody or a fragment thereof.
 54. The immunogenic fusion protein of any of claims 52-53, wherein the one or more FcRn binding domains is selected from the group consisting of an anti-FcRn antibody or a fragment thereof and a mammalian serum albumin protein or a fragment thereof.
 55. The immunogenic fusion protein of any of claims 52-54, wherein the anti-FcγR1 antibody fragment comprises SEQ ID NO:24.
 56. The immunogenic fusion protein of any of claims 52-55, wherein the fusion protein comprises at least two FcγR1 binding domains.
 57. The immunogenic fusion protein of any of claims 52-55, wherein the fusion protein comprises at least three FcγR1 binding domains.
 58. The immunogenic fusion protein of any of claims 52-57, wherein the FcRn binding domain is a fragment of human serum albumin comprising domain III.
 59. The immunogenic fusion protein of any of claims 52-57, wherein the FcRn binding domain is a variant of domain III of human serum albumin having at least 90% amino acid identity.
 60. The immunogenic fusion protein of claim 58, wherein the fragment of human serum albumin comprising domain III comprises SEQ ID NO:
 25. 61. The immunogenic fusion protein of any of claims 52-60, wherein the FcγR1 is human.
 62. The immunogenic fusion protein of any of claims 52-61, wherein the FcRn is human.
 63. The immunogenic fusion protein of any of claims 52-62, wherein the fusion protein enhances transepithelial transport of the fusion protein to the nasal-associated lymphoid tissue (NALT) and enhances FcγR1 crosslinking by the fusion protein on antigen presenting cells (APC) within the NALT.
 64. The immunogenic fusion protein of any of claims 52-63, wherein the antigen is selected from the group consisting of hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBcAg), and hepatitis B e antigen (HBeAg), NS3, NS4a, NS5a and NS5b, HPV E6/E7, EBV LMP, HBV, HCV, mutated k-ras, p53, bcr-abl, HER-2, hTERT, ganglioside GD3, NY-ESO-1, MAGE/BAGE/GAGE, Hu, Yo, GAD, MART-1/melan-A, gp-100, tyrosinase, PSA and combinations thereof.
 65. The immunogenic fusion protein of any of claims 52-64, further comprising a cleavable protein sequence and/or affinity tag to aid in purification.
 66. The immunogenic fusion protein of any of claims 65, wherein the affinity tag comprises at least 6 histidine residues.
 67. The immunogenic fusion protein of any of claims 52-66, further comprising a secretion signal to facilitate secretion of the protein through plasma membrane.
 68. The immunogenic fusion protein of claim 67, wherein the secretion signal is a lysozyme secretion signal.
 69. A nucleic acid sequence encoding the immunogenic fusion protein of any of claims 52-68.
 70. A vector comprising the nucleic acid sequence of claim
 69. 71. The vector of claim 70, wherein the vector comprises the sequence of SEQ ID NO:17.
 72. The vector of claim 70, wherein the vector comprises the sequence of SEQ ID NO:18.
 73. A pharmaceutical composition comprising a fusion protein of any of claims 52-68 and a pharmaceutically acceptable carrier.
 74. The pharmaceutical composition of claim 73, wherein the composition comprises a plurality of different fusion proteins, wherein each fusion protein comprises a different cancer antigen.
 75. The pharmaceutical composition of claim 74, wherein the different cancer antigens are from the same cancer.
 76. The pharmaceutical composition of claim 74, wherein the different cancer antigens are from different cancers.
 77. The pharmaceutical composition of any of claims 73-76, wherein the composition lacks an adjuvant.
 78. A pharmaceutical composition comprising the nucleic acid molecule of any of claims 69-72 and a pharmaceutically acceptable carrier.
 79. The pharmaceutical composition of claim 78, formulated as a nucleic acid vaccine.
 80. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of an immunogenic fusion protein of any of claims 52-68.
 81. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of nucleic acid of any of claims 69-72.
 82. The method of claim 80 or 81, wherein the subject is administered a single dose.
 83. The method of claim 80 or 81, wherein the subject is administered one or more sequential doses.
 84. An immunogenic fusion protein for use as a mucosal vaccine comprising: i) one or more FcγR1-binding domains; ii) one or more antigen binding components that bind antigen from one or more infectious disease organisms; and iii) one or more FcRn-binding domains.
 85. The immunogenic fusion protein of claim 84, wherein the one or more FcγR1 binding domains is an anti-FcgR1 antibody or a fragment thereof.
 86. The immunogenic fusion protein of any of claims 84-85, wherein the one or more FcRn binding domains is selected from the group consisting of an anti-FcRn antibody or a fragment thereof and a mammalian serum albumin protein or a fragment thereof.
 87. The immunogenic fusion protein of any of claims 84-86, wherein the anti-FcγR1 antibody fragment comprises SEQ ID NO:24.
 88. The immunogenic fusion protein of any of claims 84-87, wherein the fusion protein comprises at least two FcγR1 binding domains.
 89. The immunogenic fusion protein of any of claims 84-87, wherein the fusion protein comprises at least three FcγR1 binding domains.
 90. The immunogenic fusion protein of any of claims 84-89, wherein the FcRn binding domain is a fragment of human serum albumin comprising domain III.
 91. The immunogenic fusion protein of any of claims 84-89, wherein the FcRn binding domain is a variant of domain III of human serum albumin having at least 90% amino acid identity.
 92. The immunogenic fusion protein of claim 90, wherein the fragment of human serum albumin comprising domain III comprises SEQ ID NO:
 25. 93. The immunogenic fusion protein of any of claims 84-92, wherein the infectious disease organism is a bacterial or viral pathogen.
 94. The immunogenic fusion protein of any of claims 84-93, wherein the FcγR1 is human.
 95. The immunogenic fusion protein of any of claims 84-94, wherein the FcRn is human.
 96. The immunogenic fusion protein of claim 93, wherein the pathogen is selected from the group consisting of Streptococcus pneumonia, Neisseria meningitidis, Haemophilus influenza, Klebsiella spp., Pseudomonas spp., Salmonella spp., Shigella spp., and Group B streptococci, Bacillus anthracis adenoviruses; Bordetella pertussus; Botulism; bovine rhinotracheitis; Brucella spp.; Branhamella catarrhalis; canine hepatitis; canine distemper; Chlamydiae; Cholera; coccidiomycosis; cowpox; tularemia; filoviruses; arenaviruses; bunyaviruses; cytomegalovirus; cytomegalovirus; Dengue fever; dengue toxoplasmosis; Diphtheria; encephalitis; Enterotoxigenic Escherichia coli; Epstein Barr virus; equine encephalitis; equine infectious anemia; equine influenza; equine pneumonia; equine rhinovirus; feline leukemia; flavivirus; Burkholderia mallei; Globulin; Haemophilus influenza type b; Haemophilus influenzae; Haemophilus pertussis; Helicobacter pylori; Hemophilus spp.; hepatitis; hepatitis A; hepatitis B; Hepatitis C; herpes viruses; HIV; HIV-1 viruses; HIV-2 viruses; HTLV; Influenza; Japanese encephalitis; Klebsiellae spp. Legionella pneumophila; leishmania; leprosy; lyme disease; malaria immunogen; measles; meningitis; meningococcal; Meningococcal Polysaccharide Group A, Meningococcal Polysaccharide Group C; mumps; Mumps Virus; mycobacteria; Mycobacterium tuberculosis; Neisseria spp; Neisseria gonorrhoeae; ovine blue tongue; ovine encephalitis; papilloma; SARS and associated coronaviruses; parainfluenza; paramyxovirus; paramyxoviruses; Pertussis; Plague; Coxiella bumetti; Pneumococcus spp.; Pneumocystis carinii; Pneumonia; Poliovirus; Proteus species; Pseudomonas aeruginosa; rabies; respiratory syncytial virus; rotavirus; Rubella; Salmonellae; schistosomiasis; Shigellae; simian immunodeficiency virus; Smallpox; Staphylococcus aureus; Staphylococcus spp.; Streptococcus pyogenes; Streptococcus spp.; swine influenza; tetanus; Treponema pallidum; Typhoid; Vaccinia; varicella-zoster virus; and Vibrio cholera and combinations thereof.
 97. The immunogenic fusion protein of any of claims 84-96, wherein the fusion protein enhances transepithelial transport of the fusion protein to the nasal-associated lymphoid tissue (NALT) and enhances FcγR1 crosslinking by the fusion protein on antigen presenting cells (APC) within the NALT.
 98. The immunogenic fusion protein of any of claims 84-97, wherein the antigen is selected from the group consisting of: PspA (Streptococcus pneumonia), gp120 (HIV), hemagglutinin (influenza) and neuraminidase (influenza).
 99. The immunogenic fusion protein of any of claims 84-98, further comprising a cleavable protein sequence and/or affinity tag to aid in purification.
 100. The immunogenic fusion protein of any of claims 99, wherein the affinity tag comprises at least 6 histidine residues.
 101. The immunogenic fusion protein of any of claims 84-100, further comprising a secretion signal to facilitate secretion of the protein through plasma membrane.
 102. The immunogenic fusion protein of claim 101, wherein the secretion signal is a lysozyme secretion signal.
 103. The immunogenic fusion protein of any of claims 84-102, wherein upon administration to a subject, the fusion protein generates protection against both mucosal and non-mucosal pathogens.
 104. The immunogenic fusion protein of any of claims 84-103, wherein upon administration to a subject, the fusion protein generates protection at mucosal and non-mucosal sites.
 105. The immunogenic fusion protein of any of claims 84-104, wherein the antigen is carbohydrate antigen.
 106. The immunogenic fusion protein of any of claims 84-105, wherein the one or more antigen binding components comprises C reactive protein (CRP) or a fragment thereof, C3 or a fragment thereof, myelin basic protein (MBP) or a fragment thereof, CD6 or a fragment thereof, CD163 or a fragment thereof, and combinations thereof.
 107. A nucleic acid sequence encoding the immunogenic fusion protein of any of claims 84-106.
 108. A vector comprising the nucleic acid sequence of claim
 107. 109. The vector of claim 108, wherein the vector can be used as a nucleic acid vaccine.
 110. The vector of claim 109, wherein the vector comprises the sequence of SEQ ID NO:17.
 111. The vector of claim 109, wherein the vector comprises the sequence of SEQ ID NO:18.
 112. A pharmaceutical composition comprising a fusion protein of any of claims 84-106 and a pharmaceutically acceptable carrier.
 113. The pharmaceutical composition of claims 112, wherein the composition lacks an adjuvant.
 114. A pharmaceutical composition comprising the nucleic acid molecule of any of claims 107-111 and a pharmaceutically acceptable carrier.
 115. The pharmaceutical composition of claim 114, formulated as a nucleic acid vaccine.
 116. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of an immunogenic fusion protein of any of claims 84-106.
 117. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of nucleic acid of any of claims 107-111.
 118. The method of claim 116 or 117, wherein the subject is administered a single dose.
 119. The method of claim 116 or 117, wherein the subject is administered one or more sequential doses.
 120. The method of claim 119, wherein the fusion protein or nucleic acid is administered as a component of a homologous or heterologous prime/boost vaccine regimen.
 121. The method of claim 120, wherein the fusion protein is administered as a prime and is subsequently boosted by administration of the nucleic acid to the subject.
 122. The method of claim 120, wherein the nucleic acid is administered as a prime and is subsequently boosted by administration of the fusion protein to the subject.
 123. The method of claim 120, wherein the fusion protein is administered as a prime and is subsequently boosted by administration of the fusion protein to the subject.
 124. The method of claim 120, wherein the nucleic acid is administered as a prime and is subsequently boosted by administration of the nucleic acid to the subject.
 125. The method of any of claims 116-124, wherein the subject is human.
 126. The method of claim 117, wherein the nucleic acid is administered intradermally or intranasally.
 127. The method of claim 126, wherein intranasal administration induces secretion of the immunogenic fusion protein into the nasal tract. 